

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

Cumulative Supplement 5

MAY 1998

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

CUMULATIVE SUPPLEMENT 5
MAY 1998

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 18th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 18th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 19th Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne PLSN [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)

NO APPLICANT NAME CHANGES - MAY 1998

1.3 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG

Novopharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acylcovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.4 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Alcon's NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.5 FOLLITROPIN ALFA AND BETA

Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

1.6 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

The following *Approved Drug Products with Therapeutic Equivalence Evaluations* files are available on Internet: Prescription Drug Product List; OTC Drug Products; Discontinued Drug Products; Prescription and OTC Drug Product Patent and Exclusivity Data; and Appendices.

These files may be accessed on the Internet's World Wide Web. To access the CDER Home Page, use this Uniform Resource Locator (URL): http://www.fda.gov/cder. You do not need an Internet connection to reach the FDA Home Page; you can use the free dial-up connection (800) 222-0185 for text based, non-graphical use only. For further assistance, please call (301) 443-4908.

The Prescription Drug Products and OTC Drug Product files will be available on a monthly basis in the near future.

1.7 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1997) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1997	MAR 1998	JUN 1998	SEP 1998
DRUG PRODUCTS LISTED	9624	9711		
SINGLE SOURCE	2462 (25.6%)	2484 (25.6%)		
MULTISOURCE	7052 (73.3%)	7117 (73.3%)		
THERAPEUTICALLY EQUIVALENT	6673 (69.3%)	6746 (69.5%)		
NOT THERAPEUTICALLY EQUIVALENT	379 (4.0%)	371 (3.8%)		
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)		
NEW MOLECULAR ENTITIES APPROVED	--	8		
NUMBER OF APPLICANTS	551	529		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

ACARBOSE

TABLET; ORAL
PRECOSE

	@ BAYER	25MG	N20482 004 MAY 29, 1997
		25MG	N20482 004 MAY 29, 1997

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	ROYCE LABS	300MG;15MG	N89997 001 DEC 28, 1994
AA		300MG;30MG	N89998 001 DEC 28, 1994
AA		300MG;60MG	N89999 001 DEC 28, 1994
AA	WATSON LABS	300MG;15MG	N89997 001 DEC 28, 1994
AA		300MG;30MG	N85998 001 DEC 28, 1994
AA		300MG;60MG	N89999 001 DEC 28, 1994

ACETAMINOPHEN; HYDROCODONE BITARTRATE

ELIXIR; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	+	MIKART	500MG/15ML;7.5MG/15ML	N81051 001 AUG 20, 1992
AA		PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182 001 MAR 13, 1998

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	MALLINCKRODT	500MG;7.5MG	N40201 001 FEB 27, 1998
AA		500MG;10MG	N40201 002 FEB 27, 1998
AA	ROYCE LABS	500MG;7.5MG	N40123 003 MAR 04, 1996
AA		500MG;5MG	N40123 002 MAR 04, 1996
AA		500MG;10MG	N40123 004 MAR 04, 1996

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	ROYCE LABS	500MG;7.5MG	N40123 001 MAR 04, 1996
AA		500MG;10MG	N40123 002 MAR 04, 1996
AA		750MG;7.5MG	N40123 003 MAR 04, 1996
AA	WATSON LABS	500MG;2.5MG	N40123 003 MAR 04, 1996
AA		500MG;5MG	N40122 001 MAR 04, 1996
AA		500MG;7.5MG	N40123 004 MAR 04, 1996
AA		550MG;7.5MG	N40123 001 MAR 04, 1996
AA		650MG;10MG	N40123 002 MAR 04, 1996
AA		750MG;7.5MG	N40122 002 MAR 04, 1996

ACETAMINOPHEN; OXYCODONE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

AA	HALSEY	500MG;5MG	N40219 001 JAN 22, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

AA	ROYCE LABS	500MG;5MG	N40234 001 OCT 30, 1997
AA	WATSON LABS	500MG;5MG	N40234 001 OCT 30, 1997

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

AA	ROYCE LABS	325MG;5MG	N40171 001 OCT 30, 1997
AA	WATSON LABS	325MG;5MG	N40171 001 OCT 30, 1997

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL
PROPOXYPHENE HCL AND ACETAMINOPHEN

AA	ROYCE LABS	650MG;65MG	N40139 001 DEC 16, 1996
AA	WATSON LABS	650MG;65MG	N40139 001 DEC 16, 1996

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	B BRAUN	250MG/100ML	N18161 001
AT	MCGAW	250MG/100ML	N18161 001

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

AB	CHELSEA LABS	200MG	N75101 001 APR 15, 1998
AB	GENPHARM	200MG	N74977 001 APR 13, 1998

TABLET; ORAL
ACYCLOVIR

AB	COPLEY PHARM	400MG	N75021 001 MAR 18, 1998
AB		800MG	N75021 002 MAR 18, 1998
AB	GENPHARM	400MG	N74976 001 APR 13, 1998
AB		800MG	N74976 002 APR 13, 1998
*	NOVOPHARM	200MG	N74556 001 APR 22, 1997
●		200MG	N74556 001 APR 22, 1997

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

AP	AESGEN	EQ 500MG BASE/VIAL	N75015 001 APR 30, 1998

> ADD >
> ADD >
> ADD >
> ADD >

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

AP	APOTHECON	EQ 500MG BASE/VIAL	N74897 001 FEB 27, 1998
AP		EQ 1GM BASE/VIAL	N74897 002 FEB 27, 1998
AP	FUJISAWA	EQ 500MG BASE/VIAL	N74930 001 MAY 13, 1998
AP		EQ 1GM BASE/VIAL	N74930 002 MAY 13, 1998

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

AN	HI TECH PHARMA	EQ 0.5% BASE	N74543 001 JAN 15, 1998

SYRUP; ORAL
ALBUTEROL SULFATE

AA	HI TECH PHARMA	EQ 2MG BASE/5ML	N74749 001 JAN 30, 1998
AA	NOVA	EQ 2MG BASE/5ML	N74302 001 SEP 30, 1994
●		EQ 2MG BASE/5ML	N74302 001 SEP 30, 1994

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

AB	GENEVA PHARMS	2MG	N74909 001 MAR 25, 1998
AB	ROYCE LABS	0.25MG	N74479 001 JAN 21, 1997
AB		0.5MG	N74479 002 JAN 21, 1997
AB		1MG	N74479 003 JAN 21, 1997
AB	WATSON LABS	0.25MG	N74479 001 JAN 21, 1997
AB		0.5MG	N74479 002 JAN 21, 1997
AB		1MG	N74479 003 JAN 21, 1997

ALPROSTADIL

INJECTABLE; INJECTION
ALPROSTADIL

AP		BEDFORD	0.5MG/ML	N74815 001 JAN 20, 1998

PROSTIN VR PEDIATRIC

AP	*	PHARMACIA AND UPJOHN	0.5MG/ML	N18484 001
	*		[illegible]	[illegible]

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
SYMMETREL

AA	*	DUPONT MERCK	[illegible]	[illegible]
AA	+	ENDO PHARMS	50MG/5ML	N16023 002

TABLET; ORAL
SYMMETREL

	*	ENDO PHARMS	100MG	N18101 001
	+		100MG	N18101 001

AMCINONIDE

OINTMENT; TOPICAL
CYCLOCORT

	*	LEDERLE	0.1%	N18496 001
	+	WYETH AYERST	0.1%	N18498 001

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE

AB		ROYCE LABS	EQ 5MG ANHYDROUS;50MG	N73334 001 JUL 19, 1991
AB		WATSON LABS	EQ 5MG ANHYDROUS;50MG	N73334 001 JUL 19, 1991

AMIODARONE HYDROCHLORIDE

TABLET; ORAL
CORDARONE

AB	+	WYETH AYERST	200MG	N18972 001 DEC 24, 1985

AMIODARONE HYDROCHLORIDE

TABLET; ORAL
PACERONE

AB	UPSHER SMITH	200MG	N75135 001 APR 30, 1998

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL

AB	ROYCE LABS	[illegible]	[illegible]
AB		[illegible]	[illegible]
AB		[illegible]	[illegible]
AB		[illegible]	[illegible]
AB	WATSON LABS	10MG;2MG	OCT 17, 1991
AB		10MG;4MG	N73009 001 OCT 17, 1991
AB		25MG;2MG	N73008 001 OCT 17, 1991
AB		25MG;4MG	N73010 001 OCT 17, 1991

AMMONIUM CHLORIDE

INJECTABLE; INJECTION
AMMONIUM CHLORIDE 2.14%

	* B BRAUN	40MEQ/100ML	N85734 001
	* [illegible]	[illegible]	[illegible]

AMRINONE LACTATE

INJECTABLE; INJECTION
INOCOR

	SANOFI	[illegible]	[illegible]
	+	EQ 5MG BASE/ML	N18700 001 JUL 31, 1984

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
GENESA

		GENSIA	0.05MG/ML	N20420 001 SEP 12, 1997
	+	GENSIA AUTOMEDICS	0.05MG/ML	N20420 001 SEP 12, 1997

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

>ADD>	AB	PAR PHARM	385MG;30MG;25MG	N75141 001 MAY 29, 1998

ORPHENGESIC FORTE

>ADD>	AB	PAR PHARM	770MG;60MG;50MG	N75141 002 MAY 29, 1998

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

	AA	WATSON LABS	325MG;4.5MG;0.38MG	N40255 001 FEB 27, 1998

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

>ADD>	AB	MARTEC	50MG;25MG	N74404 001 MAY 14, 1998
>ADD>	AB		100MG;25MG	N74404 002 MAY 14, 1998

ATORVASTATIN CALCIUM

TABLET; ORAL
LIPITOR

		PARKE DAVIS	EQ 10MG BASE	N20702 001 DEC 17, 1996
			EQ 20MG BASE	N20702 002 DEC 17, 1996
	+		EQ 40MG BASE	N20702 003 DEC 17, 1996

ATORVASTATIN CALCIUM

TABLET; ORAL
LIPITOR

		WARNER LAMBERT EXPOR	EQ 10MG BASE	N20702 001 DEC 17, 1996
			EQ 20MG BASE	N20702 002 DEC 17, 1996
	+		EQ 40MG BASE	N20702 003 DEC 17, 1996

BACITRACIN

POWDER; FOR RX COMPOUNDING

>DLT>		BACITRACIN		
>DLT>		PADDOCK	5,000,000 UNITS/BOT	N62456 001 JUL 27, 1983
>ADD>		●	5,000,000 UNITS/BOT	N62456 001 JUL 27, 1983

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
NEOSPORIN

>DLT>	AT	GLAXO WELLCOME	400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50417 001
>ADD>	AT	+ MONARCH PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50417 001

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN ZINC AND POLYMYXIN B SULFATE

	AT	ADV RENEDIES	500 UNITS/GM; 10,000 UNITS/GM	N64028 001 JAN 30, 1995
	AT	AKORN	500 UNITS/GM; 10,000 UNITS/GM	N64028 001 JAN 30, 1995

POLYSPORIN

	AT	GLAXO WELLCOME	500 UNITS/GM; 10,000 UNITS/GM	N61229 001
	AT	+ MONARCH PHARMS	500 UNITS/GM; 10,000 UNITS/GM	N61229 001

BACLOFEN

TABLET; ORAL
BACLOFEN

AB	[redacted]	[redacted]	[redacted]
AB		[redacted]	[redacted]
AB	WATSON LABS	10MG	N73092 001 JAN 28, 1994
AB		20MG	N73093 001 JAN 28, 1994

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL
VASCOR

[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]
+	300MG	N19002 002 DEC 28, 1990
●	400MG	N19002 003 DEC 28, 1990

BETAMETHASONE VALERATE

CREAM; TOPICAL
BETAMETHASONE VALERATE

AB	[redacted]	[redacted]	[redacted]
●		EQ 0.1% BASE	N70053 001 JUN 10, 1986

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC
AZOPT

+	ALCON	1%	N20816 001 APR 01, 1998

BROMOCRIPTINE MESYLATE

TABLET; ORAL
BROMOCRIPTINE MESYLATE

AB	LEK PHARM	EQ 2.5MG BASE	N74631 001 JAN 13, 1998

PARLODEL

AB	+ NOVARTIS	EQ 2.5MG BASE	N17962 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML	N19864 001 JUN 10, 1993
	[redacted]	[redacted]	[redacted]

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML	N19867 001 DEC 20, 1993
	[redacted]	[redacted]	[redacted]

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML	N18256 001
AP		33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML	N20000 001 APR 17, 1992

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

AP NCGAN 33MG/100ML;30MG/100ML;30MG/100ML;
860MG/100ML N18156 001

AP 33MG/100ML;30MG/100ML;30MG/100ML;
860MG/100ML N20004 001
APR 17, 1992

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER
● B BRAUN 20MG/100ML;5GM/100ML;30MG/100ML;
600MG/100ML;310MG/100ML N17510 001
● NCGAN 20MG/100ML;5GM/100ML;30MG/100ML;
600MG/100ML;310MG/100ML N17510 001

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN PLASTIC CONTAINER
B BRAUN 35MG/100ML;30MG/100ML;74MG/100ML;
640MG/100ML;500MG/100ML;
74MG/100ML N19718 001
SEP 29, 1989
NCGAN 35MG/100ML;30MG/100ML;74MG/100ML;
640MG/100ML;500MG/100ML;
74MG/100ML N19718 001
SEP 29, 1989

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC
PLEGISOL IN PLASTIC CONTAINER
ABBOTT 17.6MG/100ML;325.3MG/100ML;
119.3MG/100ML;643MG/100ML N18608 001
FEB 26, 1982

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION/CARDIAC
PLEGISOL IN PLASTIC CONTAINER
+ ABBOTT 17.6MG/100ML;325.3MG/100ML;
119.3MG/100ML;643MG/100ML N18608 001
FEB 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
RINGER'S IN PLASTIC CONTAINER

AP B BRAUN 33MG/100ML;30MG/100ML;
860MG/100ML N18721 001
NOV 09, 1982

AP 33MG/100ML;30MG/100ML;
860MG/100ML N20002 001
APR 17, 1992

AP NCGAN 33MG/100ML;30MG/100ML;
860MG/100ML N18721 001
NOV 09, 1982

AP 33MG/100ML;30MG/100ML;
860MG/100ML N20003 001
APR 17, 1992

SOLUTION; IRRIGATION
RINGER'S IN PLASTIC CONTAINER

AT B BRAUN 33MG/100ML;30MG/100ML;
860MG/100ML N18156 001

AP NCGAN 33MG/100ML;30MG/100ML;
860MG/100ML N18156 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER

AP B BRAUN 20MG/100ML;30MG/100ML;600MG/100ML;
310MG/100ML N19632 001
FEB 29, 1988

● 20MG/100ML;30MG/100ML;600MG/100ML;
310MG/100ML N18023 001

AP NCGAN 20MG/100ML;30MG/100ML;600MG/100ML;
310MG/100ML N19632 001
FEB 29, 1988

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER

	@ MCGAW	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18681 001	

SOLUTION; IRRIGATION
LACTATED RINGER'S IN PLASTIC CONTAINER

AT	B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18681 001 DEC 27, 1982	
AT	MCGAW	[illegible]	N18681 001 DEC 27, 1982	

CAPECITABINE

TABLET; ORAL
XELODA

	ROCHE	150MG	N20896 001 APR 30, 1998	
	+	500MG	N20896 002 APR 30, 1998	

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	ROYCE LABS	12.5MG	[illegible]	
AB		25MG	[illegible]	
AB		50MG	[illegible]	
AB		100MG	[illegible]	
AB	WATSON LABS	12.5MG	FEB 13, 1996	
AB		25MG	N74451 002 FEB 13, 1996	
AB		50MG	N74451 003 FEB 13, 1996	
AB		100MG	N74451 004 FEB 13, 1996	

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL
CARBATROL

	§ ATHPHA	200MG	[illegible]	
	§	300MG	[illegible] SEP 30, 1997	
	+ SHIRE	200MG	N20712 001 SEP 30, 1997	
	+	300MG	N20712 002 SEP 30, 1997	

CARBIDOPA

TABLET; ORAL
LODOSYN

> ADD >	+ DUPONT MERCK	25MG	N17830 001	
> DLT >	§ MERCK SHARP DOHME	25MG	[illegible]	

CARBIDOPA; LEVODOPA

TABLET; ORAL
SINEMET

> ADD >	AB DUPONT MERCK	10MG;100MG	N17555 001	
> ADD >	AB	25MG;100MG	N17555 003	
> ADD >	AB +	25MG;250MG	N17555 002	
> DLT >	AB MERCK SHARP DOHME	[illegible]	[illegible]	
> DLT >	AB	[illegible]	[illegible]	
> DLT >	AB §	[illegible]	[illegible]	

TABLET, EXTENDED RELEASE; ORAL
SINEMET CR

> ADD >	DUPONT MERCK	25MG;100MG	N19856 002 DEC 24, 1992	
> ADD >	+	50MG;200MG	N19856 001 MAY 30, 1991	
> DLT >	MERCK SHARP DOHME	25MG;100MG	[illegible] DEC 24, 1992	
> DLT >	§	50MG;200MG	[illegible] MAY 30, 1991	

CARISOPRODOL

TABLET; ORAL

	CARISOPRODOL		
AA	ROXANE LABS	350MG	[illegible] DEC 03, 1998
AA	WATSON LABS	350MG	N40152 001 DEC 03, 1996

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL

	CEFACLOR		
AB	MARSAM	EQ 125MG BASE/5ML	N64204 001 FEB 18, 1998
AB		EQ 187MG BASE/5ML	N64205 001 FEB 18, 1998
AB		EQ 250MG BASE/5ML	N64206 001 FEB 18, 1998
AB		EQ 375MG BASE/5ML	N64207 001 FEB 18, 1998

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	CEFAZOLIN SODIUM		
AP	FUJISAWA	EQ 10GM BASE/VIAL	N64170 001 MAR 18, 1998
AP		EQ 20GM BASE/VIAL	N64170 002 MAR 18, 1998

CEFUROXIME SODIUM

INJECTABLE; INJECTION

	CEFUROXIME		
AB	ASTRA	EQ 750MG BASE/VIAL	N64192 002 APR 16, 1998
AP		EQ 1.5GM BASE/VIAL	N64192 001 APR 16, 1998
AP		EQ 7.5GM BASE/VIAL	N64191 001 APR 16, 1998

CEPHALEXIN

POWDER FOR RECONSTITUTION; ORAL

	KEFLEX		
*	LILLY	[illegible]	[illegible]
		EQ 100MG BASE/ML	[illegible]
@		EQ 100MG BASE/ML	N50406 003
+		EQ 100MG BASE/ML	N62117 001

CHLORAMPHENICOL

CAPSULE; ORAL

	CHLOROMYCETIN		
AB	* PARKE DAVIS	[illegible]	[illegible]
		50MG	[illegible]
	*	100MG	[illegible]
AB	+ PARKEDALE	250MG	N60591 002
		50MG	N60591 001
	+	100MG	N60591 003

OINTMENT; OPHTHALMIC

	CHLOROMYCETIN		
AT	* PARKE DAVIS	1%	[illegible]
AT	+ PARKEDALE	1%	N50156 001

POWDER FOR RECONSTITUTION; OPHTHALMIC

	CHLOROMYCETIN		
*	PARKE DAVIS	25MG/VIAL	[illegible]
+	PARKEDALE	25MG/VIAL	N50143 001

SOLUTION/DROPS; OPHTHALMIC

	OPHTHOCHLOR		
AT	PARKE DAVIS	0.5%	[illegible]
AT	PARKEDALE	0.5%	N61220 001

SOLUTION/DROPS; OTIC

	CHLOROMYCETIN		
*	PARKE DAVIS	0.5%	[illegible]
+	PARKEDALE	0.5%	N50205 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

POWDER FOR RECONSTITUTION; OPHTHALMIC

	CHLOROMYCETIN HYDROCORTISONE		
*	PARKE DAVIS	[illegible]	[illegible]
+	PARKEDALE	12.5MG/VIAL;25MG/VIAL	N50202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
OPHTHOCORT
● PARKE DAVIS — 10MG/GM;5MG/GM; 10,000 UNITS/GM — N50201 002
● PARKEDALE — 10MG/GM;5MG/GM; 10,000 UNITS/GM — N50201 002

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION
CHLOROMYCETIN
AP + PARKE DAVIS — EQ 1GM BASE/VIAL — N80188 001
AP + PARKEDALE — EQ 1GM BASE/VIAL — N50155 001

CHLORDIAZEPOXIDE

TABLET; ORAL
LIBRITABS
+ ICN — 5MG — N85482 001
● — 10MG — N85481 001
● — 25MG — N85488 001
+ ROCHE — 5MG — N85482 001
● — 10MG — N85481 001
● — 25MG — N85488 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
LIBRIUM
AB ICN — 5MG — N85461 001
AB — 10MG — N85472 001
AB + — 25MG — N85475 001
AB ROCHE — 5MG — N85461 001
AB — 10MG — N85472 001
AB + — 25MG — N85475 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
PERIDEX
AT + PROCTER AND GAMBLE — 0.12% — N19028 001 AUG 13, 1986

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
PERIDEX
AT + ZILA — 0.12% — N19028 001 AUG 13, 1986

>ADD<
>ADD<
>ADD<
>ADD<

TABLET; DENTAL
PERIOCHIP
+ PERIO PRODS (IS) — 2.5MG — N20774 001 MAY 15, 1998

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLORPROMAZINE HCL
AP WARRICK — 25MG/ML — N89563 001 APR 15, 1988
● — 25MG/ML — N89563 001 APR 15, 1988

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE
AA ROXANE LABS — 500MG — N81040 001 AUG 22, 1989
AA WATSON LABS — 500MG — N81040 001 AUG 22, 1989

CHOLESTYRAMINE

POWDER; ORAL
CHOLESTYRAMINE
AB NOVOPHARM — EQ 4GM RESIN/PACKET — N74347 001 MAY 28, 1998
AB — EQ 4GM RESIN/SCOOPFUL — N74347 002 MAY 28, 1998

CHOLESTYRAMINE LIGHT
AB NOVOPHARM — EQ 4GM RESIN/PACKET — N74348 001 MAY 28, 1998
AB — EQ 4GM RESIN/SCOOPFUL — N74348 002 MAY 28, 1998

LOCHOLEST
AB ECR — EQ 4GM RESIN/PACKET — N74561 001 AUG 15, 1996

CHOLESTYRAMINE

POWDER; ORAL

	LOCHOLEST			
AB	EON	EQ 4GM RESIN/SCOOPFUL	N74561 002	AUG 15, 1996
	●	EQ 4GM RESIN/PACKET	N74561 001	AUG 15, 1996
	●	EQ 4GM RESIN/SCOOPFUL	N74561 002	AUG 15, 1996
	LOCHOLEST LIGHT			
AB	EON	EQ 4GM RESIN/PACKET	N74562 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74562 002	AUG 15, 1996
	●	EQ 4GM RESIN/PACKET	N74562 001	AUG 15, 1996
	●	EQ 4GM RESIN/SCOOPFUL	N74562 002	AUG 15, 1996

CIMETIDINE

TABLET; ORAL

	CIMETIDINE			
>DLT<	AB	BAKER NORTON	200MG	N74424 001 JUL 28, 1995
>DLT<	AB		300MG	N74424 002 JUL 28, 1995
>DLT<	AB		400MG	N74424 003 JUL 28, 1995
>DLT<	AB		800MG	N74424 004 JUL 28, 1995
>ADD<	AB	ZENITH LABS	200MG	N74424 001 JUL 28, 1995
>ADD<	AB		300MG	N74424 002 JUL 28, 1995
>ADD<	AB		400MG	N74424 003 JUL 28, 1995
>ADD<	AB		800MG	N74424 004 JUL 28, 1995

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

CILOXAN			
+	ALCON	EQ 0.3% BASE	N20369 001 MAR 30, 1998

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC

	CIPRO HC			
+	BAYER	EQ 0.2% BASE;1%	N20805 001	FEB 10, 1998

CLEMASTINE FUMARATE

SYRUP; ORAL

	CLEMASTINE FUMARATE			
AA	MORTON GROVE	EQ 0.5MG BASE/5ML	N74863 001	MAR 13, 1998

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

	CLEOCIN 3			
+	PHARMACIA AND UPJOHN	EQ 2% BASE	N50680 002	MAR 02, 1998

INJECTABLE; INJECTION

	CLINDAMYCIN PHOSPHATE			
AP	MARSAM	EQ 12MG BASE/ML	N62913 002	OCT 20, 1988
	●	EQ 150MG BASE/ML	N62913 001	OCT 20, 1988

SOLUTION; TOPICAL

	CLEOCIN T			
AT	PHARMACIA AND UPJOHN	1% BASE	N62363 001	FEB 08, 1982
	●	EQ 1% BASE	N62363 001	FEB 08, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	CLOMIPRAMINE HCL			
AB	MYLAN	25MG	N74947 001	APR 30, 1998
AB		50MG	N74947 002	APR 30, 1998
AB		75MG	N74947 003	APR 30, 1998

CLONAZEPAM

> DLT > TABLET; ORAL
> DLT > KLONOPIN RAPIDLY DISINTEGRATING
> DLT > # ROCHE 0.125MG N20813 001
> DLT > DEC 23, 1997
> DLT > 0.25MG N20813 002
> DLT > DEC 23, 1997
> DLT > 0.5MG N20813 003
> DLT > DEC 23, 1997
> DLT > 1MG N20813 004
> DLT > DEC 23, 1997
> DLT > # 2MG N20813 005
> DLT > DEC 23, 1997

> ADD > TABLET, ORALLY DISINTEGRATING; ORAL
> ADD > KLONOPIN RAPIDLY DISINTEGRATING
> ADD > + ROCHE 0.125MG N20813 001
> ADD > DEC 23, 1997
> ADD > 0.25MG N20813 002
> ADD > DEC 23, 1997
> ADD > 0.5MG N20813 003
> ADD > DEC 23, 1997
> ADD > 1MG N20813 004
> ADD > DEC 23, 1997
> ADD > + 2MG N20813 005
> ADD > DEC 23, 1997

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION
COLY-MYCIN M
+ PARKE DAVIS EQ 150MG BASE/VIAL N50108 002
+ PARKEDALE EQ 150MG BASE/VIAL N50108 002

CORTICOTROPIN

INJECTABLE; INJECTION
ACTH
PARKE DAVIS 25 UNITS/VIAL N08317 002
40 UNITS/VIAL N08317 004
PARKEDALE 25 UNITS/VIAL N08317 002
40 UNITS/VIAL N08317 004

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC
CROLOM
AT BAUSCH AND LOMB 4% N74443 001
JAN 30, 1995
4% N74443 002
JAN 30, 1995

CROMOLYN SODIUM
AT ADV REMEDIES 4% N74706 001
APR 29, 1998

OPTICROM
AT + ALLERGAN 4% N18155 001
OCT 03, 1984
RICHER POULENC RORER 4% N18155 002
OCT 03, 1984

CYANOCOBALAMIN

INJECTABLE; IM - SC
CYANOCOBALAMIN
> ADD > AP MEDWICK 0.1MG/ML N80650 001

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL
AB ROXANE LABS 10MG N74434 002
NOV 30, 1994
AB WATSON LABS 10MG N74436 001
NOV 30, 1994

DACTINOMYCIN

INJECTABLE; INJECTION
COSMEGEN
+ MERCK 0.5MG/VIAL N50682 001
# MERCK SHARP DOHME 0.5MG/VIAL N50682 001

DALTEPARIN SODIUM

INJECTABLE; INJECTION
FRAGMIN
PHARMACIA AND UPJOHN 10,000 IU/1 ML N20287 001
JAN 10, 1996

DALTEPARIN SODIUM

INJECTABLE; INJECTION
FRAGMIN
+ PHARMACIA AND UPJOHN 10,000 IU/ML N20287 004
JAN 30, 1998

DANAZOL

CAPSULE; ORAL
DANAZOL
> ADD > AB BARR 50MG N74582 003
> ADD > MAY 29, 1998
> ADD > AB 100MG N74582 002
> ADD > MAY 29, 1998
DANOCRINE
> ADD > AB SANOFI 50MG N17557 003
> ADD > AB 100MG N17557 004

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DAUNORUBICIN HCL PRESERVATIVE FREE
+ BEDFORD EQ 20MG BASE/VIAL N50731 001
JAN 30, 1998

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
MIRCETTE
+ ORGANON 0.15MG;0.02MG N20713 001
APR 22, 1998

DESOXIMETASONE

OINTMENT; TOPICAL
DESOXIMETASONE
AB ALTANA 0.25% N73440 001
APR 01, 1998

DEXAMETHASONE SODIUM PHOSPHATE

[redacted]
@ MEDEVA EQ 0.1MG PHOSPHATE/INH N13413 001

[redacted]
[redacted] EQ 0.1MG PHOSPHATE/INH [redacted]
@ EQ 0.1MG PHOSPHATE/INH N14242 001

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 10% IN PLASTIC CONTAINER
AP B BRAUN 10GM/100ML N18046 001
[redacted] [redacted] [redacted] [redacted]
DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN 5GM/100ML N16730 001
AP 5GM/ML N16730 002
[redacted] [redacted] [redacted] [redacted]
[redacted] [redacted] [redacted]

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;31MG/100ML;130MG/100ML;
26MG/100ML;320MG/100ML N19873 001
JUN 10, 1993
[redacted] [redacted] [redacted]

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;30MG/100ML;97MG/100ML;
220MG/100ML;140MG/100ML N19844 001
JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML	N19870 001	JUN 10, 1993
	MCGAW	5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML	N19870 001	JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML	N19843 001	AUG 09, 1993
AP	MCGAW	5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML	N19843 001	AUG 09, 1993

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML	N18274 001	
AP	MCGAW	5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML	N18274 001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;75MG/100ML	N18744 001	NOV 09, 1982
AP	MCGAW	5GM/100ML;75MG/100ML	N18744 001	NOV 09, 1982

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML	N19870 001	JUN 10, 1993
	MCGAW	5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML	N19870 001	JUN 10, 1993

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

●	B BRAUN	10GM/100ML;900MG/100ML	N18047 001
●	MCGAW	10GM/100ML;900MG/100ML	N18047 001

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

●	B BRAUN	5GM/100ML;900MG/100ML	N18026 001
●	MCGAW	5GM/100ML;900MG/100ML	N18026 001

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM

AP	NARSAN	5MG/ML	N72371 001	JAN 29, 1993
	●	5MG/ML	N72371 001	JAN 29, 1993

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
DICLOFENAC SODIUM

AB	ALCON	0.1% †	N20809 001	MAY 04, 1998

VOLTAREN

AB	+ CIBA	0.1%	N20037 001	MAR 28, 1991

† SEE SECTION 1.4 OF INTRODUCTION

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL

		DICYCLOMINE HCL		
AB		BARR	20MG	[illegible]
	●		20MG	N84600 001 JUL 29, 1985

DIFLORASONE DIACETATE

CREAM; TOPICAL

		DIFLORASONE DIACETATE		
AB		ALTANA	0.05%	N75187 001 MAR 30, 1998
		PSORCON		
AB	+	DERMIK LABS	0.05%	N20205 001 NOV 20, 1992
RX	+		0.05%	[illegible]

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		DILTIAZEM HCL		
AB2		MYLAN	120MG	N75124 002 MAR 18, 1998
AB2			180MG	N75124 003 MAR 18, 1998
AB2			240MG	N75124 001 MAR 18, 1998
		TIAZAC		
> DLT >	BC	BIOVAIL	120MG	[illegible]
> DLT >				
> ADD >	BC	+	120MG	N20401 001 SEP 11, 1995
> ADD >				
> DLT >	BC		180MG	[illegible]
> DLT >				
> ADD >	BC	+	180MG	N20401 002 SEP 11, 1995
> ADD >				
> DLT >	BC		240MG	[illegible]
> DLT >				
> ADD >	BC	+	240MG	N20401 003 SEP 11, 1995
> ADD >				
> DLT >	BC		300MG	[illegible]
> DLT >				

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		TIAZAC		
> ADD >	BC	+ BIOVAIL	300MG	N20401 004 SEP 11, 1995
> ADD >				
> DLT >			360MG	[illegible]
> DLT >				
> ADD >		+	360MG	N20401 005 SEP 11, 1995
> ADD >				

INJECTABLE; INJECTION

	DILTIAZEM HCL		
AP	ABBOTT	5MG/ML	N74941 001 APR 15, 1998
AP	TAYLOR PHARMA	5MG/ML	N75086 001 APR 09, 1998

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL

	DIPHENHYDRAMINE HCL		
AA	PUREPAC PHARM	12.5MG/5ML	[illegible]
	●	12.5MG/5ML	N83237 001 JAN 25, 1982

DIPYRIDAMOLE

INJECTABLE; INJECTION

	DIPYRIDAMOLE		
AP	BEDFORD	5MG/ML	N74939 001 APR 13, 1998

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DOBUTAMINE HCL		
AP	MARSAM	EQ 12.5MG BASE/ML	N74279 001 FEB 18, 1998
AP		EQ 12.5MG BASE/ML	N74995 001 MAR 31, 1998

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
COSOPT
+ MERCK — EQ 2% BASE;EQ 0.5% BASE — N20869 001 APR 07, 1998

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL
DOXEPIN HCL
AB NOVEX LABS — EQ 10MG BASE — N72984 001 MAR 29, 1991
AB — EQ 25MG BASE — N72985 001 MAR 29, 1991
AB — EQ 50MG BASE — N72987 001 MAR 29, 1991
AB WATSON LABS — EQ 10MG BASE — N72985 001 MAR 29, 1991
AB — EQ 25MG BASE — N72986 001 MAR 29, 1991
AB — EQ 50MG BASE — N72987 001 MAR 29, 1991

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
RUBEX
AP BRISTOL MYERS — 10MG/VIAL — N62924 001 APR 13, 1989 > ADD >
AP — 50MG/VIAL — N62924 002 APR 13, 1989 > ADD >
100MG/VIAL — N62924 003 APR 13, 1989 > ADD >
AP BRISTOL MYERS SQUIBB — 10MG/VIAL — N62926 001 APR 13, 1989
AP — 50MG/VIAL — N62926 002 APR 13, 1989
100MG/VIAL — N62926 003 APR 13, 1989

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
EDROPHONIUM CHLORIDE
AP ABBOTT — 10MG/ML — N40131 001 FEB 24, 1998

ENCAINIDE HYDROCHLORIDE

CAPSULE; ORAL
ENCAID
BRISTOL MYERS SQUIBB — 25MG — N18981 002 DEC 24, 1986
35MG — N18981 003 DEC 24, 1986
● 25MG — N18981 002 DEC 24, 1986
● 35MG — N18981 003 DEC 24, 1986

ENOXAPARIN SODIUM

INJECTABLE; INJECTION
LOVENOX
+ RHONE POULENC RORER — 40MG/0.4ML — N20164 002 JAN 30, 1998
+ 60MG/0.6ML — N20164 003 MAR 27, 1998
+ 80MG/0.8ML — N20164 004 MAR 27, 1998
+ 100MG/ML — N20164 005 MAR 27, 1998

EPTIFIBATIDE

INJECTABLE; INJECTION
INTEGRILIN
+ COR — 75MG/100ML — N20718 002 MAY 18, 1998
+ 2MG/ML — N20718 001 MAY 18, 1998

ERYTHROMYCIN

OINTMENT; OPHTHALMIC
ERYTHROMYCIN
AT ADV REMEDIES — 0.5% — N64026 001 JUL 18, 1996
AT AKORN — 0.5% — N64030 001 JUL 18, 1996

OINTMENT; TOPICAL
AKNE-MYCIN
+ CTX LABS — 2% — N60164 001 JAN 18, 1985

ERYTHROMYCIN

OINTMENT; TOPICAL
AKNE-MYCIN

	+	EN INDS	2%	N50584 001 JAN 10, 1985

TABLET, DELAYED RELEASE; ORAL
E-MYCIN

AB	+	KNOLL PHARM	333MG	[illegible]
AB			333MG	N60272 002

ERY-TAB

AB		ABBOTT	250MG	[illegible]
AB	+		250MG	N62298 001
AB			333MG	[illegible] MAR 29, 1982
AB	+		333MG	N62298 003 MAR 29, 1982
AB			500MG	[illegible]
AB	+		500MG	N62298 002

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC

> ADD >	+	BAXTER PHARM PROD	10MG/ML	N19386 001 AUG 15, 1988
> ADD >				
> ADD >	●		100MG/ML	N19386 003 DEC 31, 1986
> ADD >				
> ADD >	+		250MG/ML	N19386 002 DEC 31, 1986
> ADD >				
> DLT >	+	OHMEDA	10MG/ML	[illegible]
> DLT >				
> DLT >	●		100MG/ML	[illegible]
> DLT >				
> DLT >	+		250MG/ML	[illegible]
> DLT >				

ESTAZOLAM

TABLET; ORAL
ESTAZOLAM

AB		ROXCH LABS	1MG	[illegible]
AB			2MG	[illegible] AUG 19, 1997

ESTAZOLAM

TABLET; ORAL
ESTAZOLAM

AB		WATSON LABS	1MG	N74818 001 AUG 19, 1997
AB			2MG	N74818 002 AUG 19, 1997

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
CLIMARA

BX	+	BERLEX	0.075MG/24HR	N20375 003 MAR 23, 1998

TABLET; ORAL
ESTRADIOL

AB		ENDEAVOR	0.5MG	N40138 001 JAN 30, 1998
AB			1MG	N40138 002 JAN 30, 1998
AB			2MG	N40138 003 JAN 30, 1998

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION
DEPO-ESTRADIOL

> DLT >	+	PHARMACIA AND UPJOHN	1MG/ML	[illegible]
> DLT >	+		5MG/ML	[illegible]
> ADD >	●		1MG/ML	N85470 001
> ADD >	●		3MG/ML	N85470 002

ESTRONE

INJECTABLE; INJECTION
THEELIN

	+	PARKE DAVIS	[illegible]	[illegible]
	+		[illegible]	[illegible]
	+		[illegible]	[illegible]
	●	PARKEDALE	1MG/ML	N03977 001
	●		2MG/ML	N03977 002
	●		5MG/ML	N03977 003

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21
LEVORA 0.15/30-21

AB	SEARLE	0.03MG;0.15MG	N73594 001 DEC 13, 1993	
AB	WATSON LABS	0.03MG;0.15MG	N73592 001 DEC 13, 1993	

TABLET; ORAL-28
LEVORA 0.15/30-28

AB	SEARLE	0.03MG;0.15MG	N73594 001 DEC 13, 1993	
AB	WATSON LABS	0.03MG;0.15MG	N73594 001 DEC 13, 1993	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/35E-21

AB	ROBERTS LABS	0.035MG;1MG	N71480 001 APR 12, 1988	
AB	SEARLE	0.035MG;1MG	N71480 001 APR 12, 1988	

TABLET; ORAL-28
NORETHIN 1/35E-28

AB	ROBERTS LABS	0.035MG;1MG	N71481 001 APR 12, 1988	
AB	SEARLE	0.035MG;1MG	N71481 001 APR 12, 1988	

ETODOLAC

CAPSULE; ORAL
ETODOLAC

AB	AESGEN	300MG	N74929 001 JAN 30, 1998	
AB	TARO	200MG	N75078 001 APR 30, 1998	
AB		300MG	N75078 002 APR 30, 1998	>ADD>

TABLET; ORAL
ETODOLAC

AB	CHELSEA LABS	400MG	N75069 001 APR 16, 1998	>ADD>

ETODOLAC

TABLET; ORAL
ETODOLAC

AB	MYLAN	400MG	N75104 001 FEB 06, 1998	
AB	NOVEX LABS	400MG	N74893 001 APR 16, 1997	
AB	TARO	400MG	N75074 001 MAR 11, 1998	
AB	WATSON LABS	400MG	N74892 001 APR 16, 1997	

TABLET, EXTENDED RELEASE; ORAL
LODINE XL

+	WYETH AYERST	500MG	N20584 003 JAN 20, 1998	

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

AP	MARSAM	20MG/ML	N74968 001 JAN 09, 1998	

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION
ETOPOPHOS

*	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001 MAY 17, 1996	

ETOPOPHOS PRESERVATIVE FREE

+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001 MAY 17, 1996	
+		EQ 500MG BASE/VIAL	N20906 001 FEB 27, 1998	

FAMOTIDINE

TABLET, ORALLY DISINTEGRATING; ORAL
PEPCID RPD

	MERCK	20MG	N20752 001 MAY 28, 1998	>ADD>
+		40MG	N20752 002 MAY 28, 1998	>ADD>

FENFLURAMINE HYDROCHLORIDE

TABLET; ORAL
PONDIMIN
+ ROBINS AH — 30MG — N16616 001
● — 20MG — N16618 001

FENOFIBRATE

CAPSULE; ORAL
LIPIDIL
● ABBOTT — 100MG — N19304 001 DEC 31, 1993
● LABS FOURNIER — 100MG — N19304 001 DEC 31, 1993

TRICOR (MICRONIZED)
+ ABBOTT — 67MG — N19304 002 FEB 09, 1998

FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE
AP ABBOTT — EQ 0.05MG BASE/ML — N72786 001 SEP 24, 1991
AP + ELKINS SINN — EQ 0.05MG BASE/ML — N19101 001 JUL 11, 1984

FENTANYL CITRATE PRESERVATIVE FREE
AP ABBOTT — EQ 0.05MG BASE/ML — N72786 001 SEP 24, 1991
AP + ELKINS SINN — EQ 0.05MG BASE/ML — N19101 001 JUL 11, 1984
AP MARSAM — EQ 0.05MG BASE/ML — N74917 001 FEB 03, 1998

SUBLIMAZE
AP + JANSSEN — EQ 0.05MG BASE/ML — N16619 001

SUBLIMAZE PRESERVATIVE FREE
AP + JANSSEN — EQ 0.05MG BASE/ML — N16619 001

FLOSEQUINAN

TABLET; ORAL
MANOPLAX
KROLL PHARM — 30MG — N19960 001 DEC 30, 1992

FLOSEQUINAN

TABLET; ORAL
MANOPLAX
KROLL PHARM — 30MG — N19960 001 DEC 30, 1992
● — 50MG — N19960 001 DEC 30, 1992
● — 75MG — N19960 002 DEC 30, 1992
● — 100MG — N19960 003 DEC 30, 1992

FLUOROURACIL

INJECTABLE; INJECTION
ADRUCIL
AP PHARMACIA AND UPJOHN — 50MG/ML — N81225 001 AUG 28, 1991
AP + — 50MG/ML — N81225 001 AUG 28, 1991

FLUPHENAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
FLUPHENAZINE DECANOATE
AO KING PHARMS — 25MG/ML — N74966 001 APR 16, 1998

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL
CORDRAN-N
+ LILLY — 0.05%;EQ 3.5MG BASE/GM — N50344 001
● — 0.05%;EQ 3.5MG BASE/GM — N50346 001

OINTMENT; TOPICAL
CORDRAN-N
+ LILLY — 0.05%;EQ 3.5MG BASE/GM — N50345 001
● — 0.05%;EQ 3.5MG BASE/GM — N50345 001

FLUVOXAMINE MALEATE

TABLET; ORAL
LUVOX
● SOLVAY 25MG [illegible]
DEC 05, 1994
25MG N20243 001
DEC 05, 1994

GEMFIBROZIL

CAPSULE; ORAL
LOPID
● PARKE DAVIS 200MG [illegible]
● 300MG [illegible]
● PARKE DAVIS PHARMS 200MG N18422 001
● 300MG N18422 002

TABLET; ORAL
LOPID
AB ◆ PARKE DAVIS 600MG [illegible]
NOV 20, 1986
AB ◆ PARKE DAVIS PHARMS 600MG N18422 003
NOV 20, 1986

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	EQ 40MG BASE/100ML	N62814 008 AUG 28, 1987
AP		EQ 60MG BASE/100ML	N62814 009 AUG 28, 1987
AP		EQ 70MG BASE/100ML	N62814 010 AUG 28, 1987
AP		EQ 0.8MG BASE/ML	N62814 001 AUG 28, 1987
AP		EQ 80MG BASE/100ML	N62814 011 AUG 28, 1987
AP		EQ 90MG BASE/100ML	N62814 012 AUG 28, 1987
AP		EQ 100MG BASE/100ML	N62814 013 AUG 28, 1987
AP		EQ 1.2MG BASE/ML	N62814 002 AUG 28, 1987

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	EQ 120MG BASE/100ML	N62814 014 AUG 28, 1987
AP		EQ 1.4MG BASE/ML	N62814 003 AUG 28, 1987
AP		EQ 1.6MG BASE/ML	N62814 004 AUG 28, 1987
AP		EQ 1.8MG BASE/ML	N62814 005 AUG 28, 1987
AP		EQ 2MG BASE/ML	N62814 006 AUG 28, 1987
AP		EQ 2.4MG BASE/ML	N62814 007 [illegible]
AP	MCGAW	[illegible]	[illegible]
AP		[illegible]	[illegible]
AP		[illegible]	[illegible]
AP		[illegible]	[illegible]
AP		[illegible]	[illegible]
AP		[illegible]	[illegible]
AP		[illegible]	[illegible]
AP		[illegible]	[illegible]
AP		[illegible]	[illegible]
AP		[illegible]	[illegible]
AP		[illegible]	[illegible]
AP		[illegible]	[illegible]
AP		[illegible]	[illegible]
AP		[illegible]	[illegible]
AP		[illegible]	[illegible]

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOSPORIN

AT	+	GLAXO WELLCOME	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N60582 001
AT	+	MONARCH PHARMS	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N60582 001

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL

RAXAR

> DLT >	+	GLAXO WELLCOME	EQ 200MG BASE	N20695 001 NOV 06, 1997
> DLT >				
> ADD >			EQ 200MG BASE	N20695 001 NOV 06, 1997
> ADD >				
> ADD >			EQ 400MG BASE	N20695 002 MAY 14, 1998
> ADD >				
> ADD >	+		EQ 600MG BASE	N20695 003 MAY 14, 1998
> ADD >				

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HCL

AB	ROYCE LABS	EQ 1MG BASE	N74762 001 JUN 25, 1997
AB		EQ 2MG BASE	N74762 002 JUN 25, 1997
AB	WATSON LABS	EQ 1MG BASE	N74762 001 JUN 25, 1997
AB		EQ 2MG BASE	N74762 002 JUN 25, 1997

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

AB	PUREPAC PHARM	0.5MG	N71071 001 NOV 03, 1986
AB		1MG	N71072 001 NOV 03, 1986
AB		2MG	N71073 001 NOV 03, 1986

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

AB	PUREPAC PHARM	0.5MG	N71071 001 NOV 03, 1986
AB		1MG	N71072 001 NOV 03, 1986
AB		2MG	N71073 001 NOV 03, 1986
	●	0.5MG	N71071 001 NOV 03, 1986
	●	1MG	N71072 001 NOV 03, 1986
	●	2MG	N71073 001 NOV 03, 1986
	●	5MG	N71074 001 NOV 03, 1986
	●	10MG	N71075 001 AUG 04, 1987
	●	20MG	N71076 001 AUG 04, 1987

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

AO	BEDFORD	EQ 50MG BASE/ML	N74811 001 JAN 30, 1998

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

AP	NORGAN	EQ 5MG BASE/ML	N72516 001 FEB 25, 1993
AP		EQ 5MG BASE/ML	N72517 001 FEB 25, 1993
	●	EQ 5MG BASE/ML	N72516 001 FEB 25, 1993
	●	EQ 5MG BASE/ML	N72517 001 FEB 25, 1993

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	200 UNITS/100ML	N19953 001 JUL 20, 1992
	●	200 UNITS/100ML	N19042 001 MAR 29, 1985
AP	MCGAW	200 UNITS/100ML	N19953 001 JUL 20, 1992
	●	200 UNITS/100ML	N19042 001 MAR 29, 1985

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	● B BRAUN	5,000 UNITS/100ML	N19802 001 JUL 20, 1992
	● MCGAW	5,000 UNITS/100ML	N19802 001 JUL 20, 1992

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	● B BRAUN	200 UNITS/100ML	N19042 002 MAR 29, 1985
	● MCGAW	200 UNITS/100ML	N19042 002 MAR 29, 1985

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	4,000 UNITS/100ML	N19952 001 JUL 20, 1992
AP	MCGAW	4,000 UNITS/100ML	N19952 001 JUL 20, 1992

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5,000 UNITS/100ML	N19952 004 JUL 20, 1992
AP		10,000 UNITS/100ML	N19952 005 JUL 20, 1992
	●	5,000 UNITS/100ML	N19134 001 MAR 29, 1985
AP	MCGAW	5,000 UNITS/100ML	N19952 004 JUL 20, 1992
AP		10,000 UNITS/100ML	N19952 005 JUL 20, 1992
	●	5,000 UNITS/100ML	N19134 001 MAR 29, 1985

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	● B BRAUN	5,000 UNITS/100ML	N19802 005 JUL 20, 1992

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	● B BRAUN	10,000 UNITS/100ML	N19802 002 JUL 20, 1992
	● MCGAW	5,000 UNITS/100ML	N19802 005 JUL 20, 1992
	●	10,000 UNITS/100ML	N19802 002 JUL 20, 1992

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	● B BRAUN	5,000 UNITS/100ML	N19135 001 MAR 29, 1985
	●	5,000 UNITS/100ML	N19802 003 JUL 20, 1992
	● MCGAW	5,000 UNITS/100ML	N19135 001 MAR 29, 1985
	●	5,000 UNITS/100ML	N19802 003 JUL 20, 1992

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	● B BRAUN	1,000 UNITS/100ML	N19042 004 MAR 29, 1985
	● MCGAW	1,000 UNITS/100ML	N19042 004 MAR 29, 1985

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVAPRO HCT

	● SANOFI	12.5MG;75MG	N20758 001 SEP 30, 1997
	+	12.5MG;150MG	N20758 002 SEP 30, 1997

IRBESARTAN-HYDROCHLOROTHIAZIDE

	● SANOFI	12.5MG;75MG	N20758 001 SEP 30, 1997
	+	12.5MG;150MG	N20758 002 SEP 30, 1997

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

AB	IRVANED	250MG;15MG	A70429 001 MAR 09, 1987

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL
METHYLDOPA AND HYDROCHLOROTHIAZIDE

AB	INVAMED	25MG;15MG	N70830 001 MAR 09, 1987	> DLT >	
	@	15MG;250MG	N70829 001 MAR 09, 1987	> DLT >	
	@	25MG;250MG	N70830 001 MAR 09, 1987	> ADD >	
				> ADD >	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	BARR	25MG;37.5MG	N74970 001 JAN 06, 1998		

TABLET; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

> ADD > > ADD >	AB	BARR	25MG;37.5MG	N71251 002 MAY 05, 1998	

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL
DIOVAN HCT

		NOVARTIS	12.5MG;80MG	N20818 001 MAR 06, 1998	
	+		12.5MG;160MG	N20818 002 MAR 06, 1998	

HYDROCORTISONE

CREAM; TOPICAL
ANUSOL HC

AT		PARKE DAVIS	2.5%	N88250 001 JUN 06, 1984	> DLT > > DLT >
AT		PARKEDALE	2.5%	N88250 001 JUN 06, 1984	> ADD > > ADD >

SOLUTION; TOPICAL
TEXACORT

AT	+	GENDERM	1%	N80424 001	
AT	+	MEDICIS	1%	N80425 001	

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC
CORTISPORIN

	@	GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60613 001	
AT	+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60613 001	

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
PAREMYD

	+	AKORN	1%;0.25%	N19261 001 JAN 30, 1992
	+	ALLERGAN	1%;0.25%	N19261 001 JAN 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL
HYDROXYCHLOROQUINE SULFATE

> ADD > > ADD >	AB	MYLAN	200MG	N40274 001 MAY 29, 1998	
	AB	HYDROXYCHLOROQUINE SULFATE ROYCE LABS	200MG	N40133 001 NOV 30, 1995	
	AB	WATSON LABS	200MG	N40133 001 NOV 30, 1995	

HYDROXYUREA

CAPSULE; ORAL
DROXIA

		BRISTOL MYERS SQUIBB	300MG	N16295 003 FEB 25, 1998	> DLT > > DLT >
			200MG	N16295 002 FEB 25, 1998	
			300MG	N16295 003 FEB 25, 1998	
	+		400MG	N16295 004 FEB 25, 1998	

HYDREA

AB	+	BRISTOL MYERS SQUIBB	500MG	N16295 001	
AB	+	SQUIBB	500MG	N16295 001	

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HCL

AB	ROYCE LABS	10MG		N81149 001 MAR 18, 1994	
AB		25MG		N81150 001 MAR 18, 1994	
AB		50MG		N81151 001 MAR 18, 1994	
AB	WATSON LABS	10MG		N81149 001 MAR 18, 1994	
AB		25MG	> ADD >	N81150 001 MAR 18, 1994	
AB		50MG	> ADD >	N81151 001 MAR 18, 1994	

IBUPROFEN

SUSPENSION; ORAL
CHILDREN'S ADVIL

BX	AN HOME PRODS	100MG/5ML		N19833 002 SEP 19, 1989	
BX	WHITEHALL ROBINS	100MG/5ML		N19833 002 SEP 19, 1989	

IBUPROFEN

AB	ALPHARMA	100MG/5ML		N74978 001 MAR 25, 1998	

MOTRIN

AB	+ MCNEIL	100MG/5ML		N19842 001 SEP 19, 1989	
BX	+	100MG/5ML		N19842 001 SEP 19, 1989	

TABLET; ORAL
IBUPROFEN

AB	INVANED	400MG		N72064 001 JAN 14, 1988	
AB		600MG		N72065 001 JAN 14, 1988	
AB		800MG		N71938 001 JAN 14, 1988	
	●	400MG		N72064 001 JAN 14, 1988	
	●	600MG		N72065 001 JAN 14, 1988	
	●	800MG		N71938 001 JAN 14, 1988	

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE

AB	TEVA	1.25MG		N74498 002 FEB 12, 1998	

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

AB	EON	75MG		N74464 001 MAY 28, 1998	

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL

AP	ELKINS SINN	51%		N74629 004 MAR 31, 1998	

IOPAMIDOL-250

AP	ABBOTT	51%		N75005 001 FEB 24, 1998	

IOPAMIDOL-300

AP	ABBOTT	61%		N75005 002 FEB 24, 1998	

IOPAMIDOL-370

AP	ABBOTT	76%		N75005 003 FEB 24, 1998	

IOTROLAN

INJECTABLE; INTRATHECAL
OSMOVIST 190

	BERLEX	40.6%		N19580 001 DEC 07, 1989	
	BERLEX LABS	40.6%		N19580 001 DEC 07, 1989	

OSMOVIST 240

	BERLEX	51.3%		N19580 002 DEC 07, 1989	
	BERLEX LABS	51.3%		N19580 002 DEC 07, 1989	

IOVERSOL

INJECTABLE; INJECTION
OPTIRAY 240
> ADD > + MALLINCKRODT 51% N20923 001
> ADD > MAY 28, 1998
OPTIRAY 320
> ADD > + MALLINCKRODT 68% N20923 002
> ADD > MAY 29, 1998
OPTIRAY 350
> ADD > + MALLINCKRODT 74% N20923 003
> ADD > MAY 28, 1998

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION
ATROVENT
[redacted] 0.018MG/INH [redacted]
[redacted]
+ 0.018MG/INH N19085 001
DEC 29, 1986

ISOSULFAN BLUE

INJECTABLE; INJECTION
LYMPHAZURIN
+ [redacted] 1% [redacted]
+ US SURGCL 1% N18310 001

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETALAR
AP + PARKE DAVIS [redacted] [redacted]
AP + [redacted] [redacted]
+ [redacted] [redacted]
AP + PARKEDALE [redacted] N16812 002
AP + [redacted] N16812 003
+ [redacted] N16812 001

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL
ORUVAIL
+ WYETH AYERST 100MG N19816 003
FEB 08, 1995

> DLT >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
> ADD >
> ADD >

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL
ORUVAIL
+ [redacted] [redacted] [redacted]
100MG N19816 003
FEB 08, 1995
150MG N19816 002
FEB 08, 1995

LEPIRUDIN

INJECTABLE; INJECTION
REFLUDAN
+ HOECHST MARION RSSL 50MG/VIAL N20807 001
MAR 06, 1998

LIDOCAINE; PRILOCAINE

DISC; TOPICAL
EMLA
+ ASTRA 2.5%;2.5% N20962 001
FEB 04, 1998

LORATADINE

[redacted]
[redacted]
[redacted] 10MG [redacted]

TABLET, ORALLY DISINTEGRATING; ORAL
CLARITIN REDITABS
+ SCHERING 10MG N20704 001
DEC 23, 1996

LORAZEPAM

TABLET; ORAL
LORAZEPAM
AB [redacted] [redacted] [redacted]
AB [redacted] [redacted]

LORAZEPAM

TABLET; ORAL
LORAZEPAM

AB	NOVOPHARM	[illegible]	[illegible]
AB	WATSON LABS	0.5MG	N72926 001 OCT 31, 1991
AB		1MG	N72927 001 OCT 31, 1991
AB		2MG	N72928 001 OCT 31, 1991

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC
ALREX

+	PHARMOS	0.2%	N20803 001 MAR 09, 1998

LOTEMAX

+	PHARMOS	0.5%	N20583 001 MAR 09, 1998
+		0.5%	N20841 001 MAR 09, 1998

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL
LOXITANE C

+	COCENSYS	EQ 25MG BASE/ML	[illegible]
+	WATSON LABS	EQ 25MG BASE/ML	N17658 001

INJECTABLE; INJECTION
LOXITANE IM

+	COCENSYS	EQ 50MG BASE/ML	[illegible]
+	WATSON LABS	EQ 50MG BASE/ML	N18039 001

LOXAPINE SUCCINATE

CAPSULE; ORAL
LOXITANE

AB	COCENSYS	[illegible]	[illegible]
AB		[illegible]	[illegible]
AB	+	[illegible]	[illegible]
AB		[illegible]	[illegible]
AB	WATSON LABS	EQ 5MG BASE	N17525 001

LOXAPINE SUCCINATE

CAPSULE; ORAL
LOXITANE

AB	WATSON LABS	EQ 10MG BASE	N17525 002
AB	+	EQ 25MG BASE	N17525 003
AB		EQ 50MG BASE	N17525 004

TABLET; ORAL
LOXITANE

●	COCENSYS	[illegible]	[illegible]
●		[illegible]	[illegible]
●		[illegible]	[illegible]
●	WATSON LABS	EQ 10MG BASE	N17525 006
●		EQ 25MG BASE	N17525 007
●		EQ 50MG BASE	N17525 008

MAFENIDE ACETATE

CREAM; TOPICAL
SULFAMYLON

+	BERTEK PHARMS	EQ 85MG BASE/GM	N16763 001
+	MYLAN MYCOAN	[illegible]	[illegible]

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML	N19696 001 SEP 29, 1989
	MCGAW	[illegible]	[illegible]

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN PLASTIC CONTAINER

AP	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N18252 001

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN PLASTIC CONTAINER

AP	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N19711 001 SEP 29, 1989
AP	MCGAW	30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N18252 001
AP		30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N19711 001 SEP 29, 1989

MALATHION

LOTION; TOPICAL
OVIDE

*	GENDERM	0.5%	N18613 001 AUG 02, 1982
*	MEDICIS	0.5%	N18613 001 AUG 02, 1982

MANNITOL

INJECTABLE; INJECTION
MANNITOL 10% IN PLASTIC CONTAINER

AP	B BRAUN	10GM/100ML	N20006 002 JUL 26, 1993
AP	MCGAW	10GM/100ML	N20006 002 JUL 26, 1993

MANNITOL 15% IN PLASTIC CONTAINER

AP	B BRAUN	15GM/100ML	N20006 003 JUL 26, 1993
AP	MCGAW	15GM/100ML	N20006 003 JUL 26, 1993

MANNITOL 20%

AP	B BRAUN	20GM/100ML	N14738 001
AP	MCGAW	20GM/100ML	N14738 001

MANNITOL 20% IN PLASTIC CONTAINER

AP	B BRAUN	20GM/100ML	N20006 004 JUL 26, 1993
AP	MCGAW	20GM/100ML	N20006 004 JUL 26, 1993

MANNITOL 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML	N20006 001 JUL 26, 1993

MANNITOL

INJECTABLE; INJECTION
MANNITOL 5% IN PLASTIC CONTAINER

AP	MCGAW	5GM/100ML	N20006 001 JUL 26, 1993

SOLUTION; IRRIGATION
RESECTISOL IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML	N16772 002
	MCGAW	5GM/100ML	N16772 002

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL
INVERSINE

+	LAYTON	2.5MG	N10251 001
+	MERCK SHARP DOHME	2.5MG	N10251 001

MEGESTROL ACETATE

TABLET; ORAL
MEGESTROL ACETATE

AB	PHARMACHEMIE	40MG	N74745 001 FEB 27, 1998

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL
MEPERIDINE HCL

AA	ROYCE LABS	50MG	M40186 001 JUN 30, 1997
AA	WATSON LABS	50MG	M40186 001 JUN 30, 1997

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/50M-21

AB	ROBERTS LABS	0.05MG;1MG	N71539 001 APR 12, 1988
AB	SEARLE	0.05MG;1MG	N71539 001 APR 12, 1988

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28
NORETHIN 1/50M-28

AB	ROBERTS LABS	0.05MG;1MG	N71540 001 APR 12, 1988
AB	SEARLE	0.05MG;1MG	N71540 001 APR 12, 1988

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL
METHADONE HCL

AA	ROXANE	10MG/ML	N40180 001 APR 30, 1998

TABLET; ORAL
METHADONE HCL

> ADD >	AA	EON	5MG	N40241 001 MAY 29, 1998
> ADD >	AA		10MG	N40241 002 MAY 29, 1998

TABLET, DISPERSIBLE; ORAL
METHADONE HCL

AA	EON	40MG	N75082 001 MAR 25, 1998

METHOCARBAMOL

INJECTABLE; INJECTION
METHOCARBAMOL

AP	MARSAN	100MG/ML	N89849 001 DEC 27, 1991
	●	100MG/ML	N89849 001 DEC 27, 1991

METOCLOPRAMILE HYDROCHLORIDE

TABLET; ORAL
METOCLOPRAMIDE HCL

AB	INVAMED	EQ 5MG BASE	N72436 001 JUN 22, 1989
AB		EQ 10MG BASE	N70850 001 FEB 03, 1987

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL
METOCLOPRAMIDE HCL

●	INVAMED	EQ 5MG BASE	N72436 001 JUN 22, 1989
●		EQ 10MG BASE	N70850 001 FEB 03, 1987

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	DANBURY PHARMA	150MG	N74865 001 APR 13, 1998
AB		200MG	N74865 002 APR 13, 1998
AB		250MG	N74865 003 APR 13, 1998

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

AP	SUPERGEN	5MG/VIAL	N64144 001 APR 30, 1998
AP		20MG/VIAL	N64144 002 APR 30, 1998

MONTELUKAST SODIUM

TABLET; ORAL
SINGULAR

+	MERCK	EQ 10MG BASE	N20829 002 FEB 20, 1998

TABLET, CHEWABLE; ORAL
SINGULAIR

+	MERCK	EQ 5MG BASE	N20830 001 FEB 20, 1998

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL

AP	KING PHARMS	10MG/ML	N74471 001	MAR 19, 1998
AP		20MG/ML	N74471 002	MAR 19, 1998

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

> DLT >	AP	ABBOTT	0.4MG/ML	N70172 001	SEP 24, 1986
> ADD >		●	0.4MG/ML	N70172 001	SEP 24, 1986

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE AND NALOXONE HYDROCHLORIDES

AB	ROYCE LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001	JAN 21, 1997
AB	WATSON LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001	JAN 21, 1997

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HCL

> ADD >	AB	BARR	50MG	N74918 001	MAY 08, 1998
> ADD >		REVIA			
> ADD >	AB	+ DUPONT MERCK	50MG	N18932 001	NOV 20, 1984

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
EC-NAPROSYN

AB	+ SYNTEX	375MG	N20067 002	OCT 14, 1994

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
EC-NAPROSYN

AB	+ SYNTEX	500MG	N20067 003	OCT 14, 1994
	NAPROXEN			
AB	INVAMED	375MG	N75061 001	FEB 18, 1998
AB		500MG	N75061 002	FEB 18, 1998
AB	PUREPAC PHARM	375MG	N74936 001	FEB 24, 1998
AB		500MG	N74936 002	FEB 24, 1998

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

AB	AL HIKMA	EQ 250MG BASE	N74480 002	FEB 18, 1998

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL
AMERGE

	GLAXO WELLCOME	EQ 1MG BASE	N20763 002	FEB 10, 1998
	+	EQ 2.5MG BASE	N20763 001	FEB 10, 1998

NEOMYCIN SULFATE

TABLET; ORAL
NEOMYCIN SULFATE

> DLT >		TEVA	EQ 350MG BASE	N60304 001	
> ADD >		+	EQ 350MG BASE	N60304 001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION
NEOSPORIN G.U. IRRIGANT

AP	GLAXO WELLCOME	EQ 4MG BASE/ML; [illegible]	N60787 001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION
NEOSPORIN G.U. IRRIGANT

AT	MONARCH PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	N60707 001	

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION; ORAL
TPN SUSPENSION

+	INTL MINERALS	15MG/5ML;3.75MG/5ML; 600MG/5ML	N08378 003	

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL
NICARDIPINE HCL

AB	GENPHARM	20MG	N74928 001	MAR 19, 1998
AB		30MG	N74928 002	MAR 19, 1998

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL
MINITRAN

AB	3M	0.1MG/HR	N89771 001	AUG 30, 1996
AB1		0.1MG/HR	N89771 001	AUG 30, 1996
AB		0.2MG/HR	N89772 001	AUG 30, 1996
AB1		0.2MG/HR	N89772 001	AUG 30, 1996
AB		0.4MG/HR	N89773 001	AUG 30, 1996
AB1		0.4MG/HR	N89773 001	AUG 30, 1996
AB		0.6MG/HR	N89774 001	AUG 30, 1996
AB1		0.6MG/HR	N89774 001	AUG 30, 1996

NITRO-DUR

AB	+ KEY PHARMS	0.1MG/HR	N20145 001	APR 04, 1995

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL
NITRO-DUR

AB1	+ KEY PHARMS	0.1MG/HR	N20145 001	APR 04, 1995
AB	+	0.2MG/HR	N20145 002	APR 04, 1995
AB1	+	0.2MG/HR	N20145 002	APR 04, 1995
AB	+	0.4MG/HR	N20145 004	APR 04, 1995
AB1	+	0.4MG/HR	N20145 004	APR 04, 1995
AB	+	0.6MG/HR	N20145 005	APR 04, 1995
AB1	+	0.6MG/HR	N20145 005	APR 04, 1995

NITROGLYCERIN

AB2	MYLAN	0.1MG/HR	N75033 001	FEB 06, 1998
AB		0.2MG/HR	N74609 001	AUG 30, 1996
AB2		0.2MG/HR	N74609 001	AUG 30, 1996
AB		0.4MG/HR	N74607 001	AUG 30, 1996
AB2		0.4MG/HR	N74607 001	AUG 30, 1996
AB		0.6MG/HR	N74559 001	AUG 30, 1996
AB2		0.6MG/HR	N74559 001	AUG 30, 1996

TRANSDERM-NITRO

AB2	+ NOVARTIS	0.1MG/HR	N20144 001	FEB 27, 1996
AB	+	0.2MG/HR	N20144 002	FEB 27, 1996
AB2	+	0.2MG/HR	N20144 002	FEB 27, 1996
AB	+	0.4MG/HR	N20144 003	FEB 27, 1996
AB2	+	0.4MG/HR	N20144 003	FEB 27, 1996
AB	+	0.6MG/HR	N20144 004	FEB 27, 1996
AB2		0.6MG/HR	N20144 004	FEB 27, 1996

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL
TRANSDERM-NITRO
RX + NOVARTIS 0.1MG/HR N20144 001 FEB 27, 1998

NORETHINDRONE

TABLET; ORAL
NOR-QD
+ SEARLE 0.35MG N17060 001
+ WATSON LABS 0.35MG N17060 001

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC
+ ASTRA MERCK 40MG N19810 002 JAN 15, 1998

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
DITROPAN
AA + ALZA 5MG/5ML N18211 001
AA + HOECHST MARION RSSL 5MG/5ML N18211 001

TABLET; ORAL
DITROPAN
AB + ALZA 5MG N17577 001
AB + HOECHST MARION RSSL 5MG N17577 001

OXYTOCIN

INJECTABLE; INJECTION
PITOCIN
AP + KING PHARMS 10 USP UNITS/ML N18261 001
AP + PARKEDALE 10 USP UNITS/ML N18261 001

PARICALCITOL

INJECTABLE; INJECTION
ZEMPLAR
+ ABBOTT 0.005MG/ML N20819 001 APR 17, 1998

PAROMOMYCIN SULFATE

CAPSULE; ORAL
HUMATIN
AB + PARKE DAVIS EQ 250MG BASE N60521 001
AB EQ 250MG BASE N62310 001
AB + PARKEDALE EQ 250MG BASE N60521 001
AB EQ 250MG BASE N62310 001

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL
ELMIRON
+ ALZA 100MG N20193 001 SEP 26, 1996
+ BAKER NORTON 100MG N20193 001 SEP 26, 1996

PERMETHRIN

CREAM; TOPICAL
ELIMITE
AB + ALLERGAN 5% N19855 001 AUG 25, 1989

PERMETHRIN
AB ALPHARMA 5% N74806 001 JAN 23, 1998

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL
AZO GANTRISIN
+ ROCHE 50MG;500MG N18358 001 AUG 31, 1990
@ 50MG;500MG N19358 001 AUG 31, 1990

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL

> DLT >	AA	ECN	37.5MG	N88414 001 OCT 19, 1983
> DLT >				
> ADD >		●	37.5MG	N88414 001 OCT 19, 1983
> ADD >				

TABLET; ORAL
PHENTERMINE HCL

> DLT >		+ ECN	30MG	N88605 001 SEP 28, 1987
> DLT >				
> ADD >		●	30MG	N88605 001 SEP 28, 1987
> ADD >				

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION
PHENTOLAMINE MESYLATE

AP		BEDFORD	5MG/VIAL	N40235 001 MAR 11, 1998

REGITINE

AP	+	NOVARTIS	5MG/VIAL	N08278 003

PINDOLOL

TABLET; CRAL
PINDOLOL

AB		PUREPAC PHARM	5MG	N74125 001 APR 28, 1993
AB			10MG	N74125 002 APR 28, 1993
		●	5MG	N74125 001 APR 28, 1993
		●	10MG	N74125 002 APR 28, 1993
AB		ROYCE LABS	5MG	N74437 001 FEB 27, 1995
AB			10MG	N74437 002 FEB 27, 1995
AB		WATSON LABS	5MG	N74437 001 FEB 27, 1995
AB			10MG	N74437 002 FEB 27, 1995

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
ZOSYN IN PLASTIC CONTAINER

+	LEDERLE	EQ 40MG BASE/ML; EQ 5MG BASE/ML	N50750 001 FEB 24, 1998
+		EQ 4GM BASE/100ML; EQ 500MG BASE/100ML	N50750 003 FEB 24, 1998
+		EQ 60MG BASE/ML; EQ 7.5MG BASE/ML	N50750 002 FEB 24, 1998

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	ROYCE LABS	10MG	N74460 001 SEP 29, 1995
AB		20MG	N74460 002 SEP 29, 1995
AB	WATSON LABS	10MG	N74460 001 SEP 29, 1995
AB		20MG	N74460 002 SEP 29, 1995

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
PEG-LYTE

AA	INVAMED	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N73098 001 AUG 31, 1993
	●	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N73098 001 AUG 31, 1993

POLYMYXIN B SULFATE

INJECTABLE; INJECTION
AEROSPORIN

AP	+	GLAXO WELLCOME	EQ 500,000 U BASE/VIAL	N62036 001
		●	EQ 500,000 U BASE/VIAL	N62036 001

POLYMYXIN B SULFATE

AP		PFIZER	EQ 500,000 U BASE/VIAL	N60716 001

POLYMYXIN B SULFATE

INJECTABLE; INJECTION
POLYMYXIN B SULFATE

	AP	+	PFIZER	EQ 500,000 U BASE/VIAL	N60716 001

POWDER; FOR RX COMPOUNDING
POLY-RX

> DLT >	AA		PHARMA TEK	100,000,000 UNITS/BOT	N61578 001
> ADD >		+		100,000,000 UNITS/BOT	N61578 001
> DLT >			POLYMYXIN B SULFATE		
> DLT >	AA		PADDOCK	100,000,000 UNITS/BOT	N62455 001
> DLT >					JUL 27, 1983
> ADD >		@		100,000,000 UNITS/BOT	N62455 001
> ADD >					JUL 27, 1983

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT		ALCON	10,000 UNITS/ML; EQ 1MG BASE/ML	N64211 001
				APR 13, 1998

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

AP		B BRAUN	2MEQ/ML	N05070 001
AP		MCGAW	2MEQ/ML	N05070 001

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

@	B BRAUN	75MG/100ML;900MG/100ML	N18722 001
			NOV 09, 1982
@	MCGAW	75MG/100ML;900MG/100ML	N18722 001
			NOV 09, 1982

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

@	B BRAUN	150MG/100ML;900MG/100ML	N18722 002
			NOV 09, 1982
@	MCGAW	150MG/100ML;900MG/100ML	N18722 002
			NOV 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

@	B BRAUN	220MG/100ML;900MG/100ML	N18722 003
			NOV 09, 1982
@	MCGAW	220MG/100ML;900MG/100ML	N18722 003
			NOV 09, 1982

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@	B BRAUN	300MG/100ML;900MG/100ML	N18722 004
			NOV 09, 1982
@	MCGAW	300MG/100ML;900MG/100ML	N18722 004
			NOV 09, 1982

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL
MIRAPEX

	PHARMACIA AND UPJOHN	0.5MG	N20667 006
			FEB 12, 1998

PREDNISOLONE

SYRUP; ORAL

> ADD >			PRE-PRED		
> ADD >	AA		WE PHARMS	15MG/5ML	N40192 001
> ADD >					MAY 28, 1998
			PRELONE		
> ADD >	AA	+	MURO	15MG/5ML	N89081 001
> ADD >					FEB 04, 1986

TABLET; ORAL
PREDNISOLONE

BX		DANBURY PHARMA	5MG	N80354 002
BX	+		5MG	N80354 001
BX	+	GENEVA PHARMS	5MG	N80339 001
	@		5MG	N80339 001

PRIMIDONE

SUSPENSION; ORAL
MYSOLINE

	+	ELAN PHARMA	250MG/5ML	N10401 001
	+	WYETH AYERST	250MG/5ML	N10401 001

PRIMIDONE

TABLET; ORAL

MYSOLINE

AB	+	ELAN PHARMA	250MG	N09170 002
	+		50MG	N09170 003
AB	+	WYETH AYERST	250MG	N09170 002
	+		50MG	N09170 003

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HCL

AB		INVAMED	500MG	N89284 001 JUN 23, 1986
	@		500MG	N89284 001 JUN 23, 1986
> DLT > > DLT > > ADD > > ADD > AB		SIDMAK LABS NJ	250MG	N88958 001 DEC 02, 1985
	@		250MG	N88958 001 DEC 02, 1985

PROCAN SR

AB		PARKE DAVIS	500MG	N86065 001
AB			750MG	N87510 001 APR 01, 1982
AB	+		1GM	N88489 001 JAN 16, 1985
AB	+	PARKEDALE	500MG	N86065 001
AB	+		750MG	N87510 001 APR 01, 1982
AB	+		1GM	N88489 001 JAN 16, 1985

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP		MARSAN	EQ 5MG BASE/ML	N89675 001 DEC 05, 1988
	@		EQ 5MG BASE/ML	N89675 001 DEC 05, 1988

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

AB		TRIGEN	EQ 5MG BASE	N40268 001 FEB 27, 1998
AB			EQ 10MG BASE	N40268 002 FEB 27, 1998
AB		ZENITH GOLDLINE	EQ 5MG BASE	N40162 001 JAN 20, 1998
AB			EQ 10MG BASE	N40162 002 JAN 20, 1998

PROGESTERONE

> ADD >		CAPSULE; ORAL		
> ADD >		PROMETRIUM		
> ADD >	+	SCHERING PLOUGH	100MG	N19781 001 MAY 14, 1998

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HCL

AP		MARSAN	25MG/ML	N89463 001 MAY 02, 1988
AP			50MG/ML	N89477 001 MAY 02, 1988
	@		25MG/ML	N89463 001 MAY 02, 1988
	@		50MG/ML	N89477 001 MAY 02, 1988

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HCL

AA		PUREPAC PHARM	65MG	N83278 001
	@		65MG	N83278 001

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL

AB		INVAMED	10MG	N71698 001 JUL 05, 1988

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	INVAMED	20MG		N71687 001 JUL 05, 1988
AB		40MG		N71688 001 JUL 05, 1988
AB		60MG		N72197 001 JUL 05, 1988
AB		80MG		N71689 001 JUL 05, 1988
AB		90MG		N72198 001 JUL 05, 1988
	@	10MG		N71658 001 JUL 05, 1988
	@	20MG		N71687 001 JUL 05, 1988
	@	40MG		N71688 001 JUL 05, 1988
	@	60MG		N72197 001 JUL 05, 1988
	@	80MG		N71689 001 JUL 05, 1988
	@	90MG		N72198 001 JUL 05, 1988

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

AB	PUREPAC PHARM	200MG		N84003 001
	@	200MG		N84003 001

RANITIDINE HYDROCHLORIDE

SYRUP; ORAL
ZANTAC

	GLAXO WELLCOME	EQ 15MG BASE/ML		N19675 001 DEC 30, 1988
	+	EQ 15MG BASE/ML		N19675 001 DEC 30, 1988

TABLET; ORAL
RANITIDINE HCL

AB	RANBAXY	EQ 150MG BASE		N75000 001 JAN 30, 1998

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HCL

AB	RANBAXY	EQ 300MG BASE		N75000 002 JAN 30, 1998

RISEDRONATE SODIUM

TABLET; ORAL
ACTONEL

	+ PROCTER AND GAMBLE	30MG		N20835 001 MAR 27, 1998

SACROSIDASE

SOLUTION; ORAL
SUCRAID

	+ ORPHAN MEDCL	8,500 IU/ML		N20772 001 APR 09, 1998

SAQUINAVIR

CAPSULE; ORAL
FORTOVASE

	+ ROCHE	EQ 200MG BASE		N20828 001 NOV 07, 1997
	+	200MG		N20828 001 NOV 07, 1997

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
SELEGILINE HCL

AB	ESI LEDERLE	5MG		N74641 001 AUG 02, 1996
AB	LEDERLE	5MG		N74641 001 AUG 02, 1996
AB	STASON	5MG		N74512 001 APR 30, 1998

SILDENAFIL CITRATE

TABLET; ORAL
VIAGRA

	PFIZER	25MG	N20895 001 MAR 27, 1998	
		50MG	N20895 002 MAR 27, 1998	
+		100MG	N20895 003 MAR 27, 1998	

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	450MG/100ML	N19635 001 MAR 09, 1988	
@		450MG/100ML	N18184 001	
AP	MCGAW	450MG/100ML	N19635 001 MAR 09, 1988	
@		450MG/100ML	N18184 001	

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	900MG/100ML	N17464 001	
AP		900MG/100ML	N19635 002 MAR 09, 1988	> DLT >
AP	MCGAW	900MG/100ML	N17464 001	> DLT >
AP		900MG/100ML	N19635 002 MAR 09, 1988	> DLT > > DLT >

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

@	B BRAUN	3GM/100ML	N19635 003 MAR 09, 1988	> ADD >
@	MCGAW	3GM/100ML	N19635 003 MAR 09, 1988	> ADD > > ADD >

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

@	B BRAUN	5GM/100ML	N19635 004 MAR 09, 1988	
@	MCGAW	5GM/100ML	N19635 004 MAR 09, 1988	

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

@	B BRAUN	1.87GM/100ML	N18186 001
@	MCGAW	1.87GM/100ML	N18186 001

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

AP	B BRAUN	1.87GM/100ML	N20004 001 APR 21, 1992

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

AP	MCGAW	1.87GM/100ML	N20004 001 APR 21, 1992

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
KAYEXALATE

AA	SANOFI	453.6GM/BOT	N11287 001
AA	+	453.6GM/BOT	N11287 001

KIONEX

AA	PADDOCK	454GM/BOT	N40029 001 FEB 06, 1998

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE

P	BERLEX LABS	120MG	N19865 005 APR 20, 1994
		160MG	N19865 002 OCT 30, 1992
+		240MG	N19865 003 OCT 30, 1992
		120MG	N19865 005 APR 20, 1994
+		160MG	N19865 002 OCT 30, 1992
		240MG	N19865 003 OCT 30, 1992

SOYBEAN OIL

INJECTABLE; INJECTION
INTRALIPID 30%

AP	+	PHARMACIA AND UPJOHN	30%	N19942 001 DEC 30, 1993

LIPOSYN III 30%

AP	+	ABBOTT	30%	N20161 001 JAN 13, 1998

NUTRILIPID 10%

AP	+	B BRAUN	10%	N19531 001 MAY 28, 1993

SOYBEAN OIL

INJECTABLE; INJECTION

NUTRILIPID 10%

AP	+	MCGAW	10%	N19531 001 MAY 28, 1993

NUTRILIPID 20%

AP	+	B BRAUN	20%	N19531 002 MAY 28, 1993
AP	+	MCGAW	20%	N19531 002 MAY 28, 1993

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

> DLT >		PFIZER	EQ 1GM BASE/2.5ML	N60111 001
> ADD >	+		EQ 1GM BASE/2.5ML	N60111 001

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

SUCOSTRIN

AP	+	APOTHECON	20MG/ML	N08847 001
	@		20MG/ML	N08847 001

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTA

AP	+	AKORN	EQ 0.05MG BASE/ML	N19050 001 MAY 04, 1984
AP	+	JANSSEN	EQ 0.05MG BASE/ML	N19050 001 MAY 04, 1984

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

SMZ-TMP

AB	TEVA	200MG/5ML;40MG/5ML	N18812 001 JAN 28, 1983

SMZ-TMP PEDIATRIC

AB	TEVA	200MG/5ML;40MG/5ML	N18812 002 JUN 10, 1983

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	TEVA	200MG/5ML;40MG/5ML	N18812 001 JAN 28, 1983
AB		200MG/5ML;40MG/5ML	N18812 002 JUN 10, 1983

TABLET; ORAL

SMZ-TMP

AB	TEVA	400MG;80MG	N18242 001
AB		800MG;160MG	N18242 002

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	TEVA	400MG;80MG	N18242 001
AB		800MG;160MG	N18242 002

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE

AB	SUPERPHARM	500MG	N89339 001 OCT 26, 1987
	@	500MG	N89339 001 OCT 26, 1987

TACRINE HYDROCHLORIDE

CAPSULE; ORAL

COGNEX

	PARKE DAVIS	EQ 10MG BASE	N20070 001 SEP 09, 1993
		EQ 20MG BASE	N20070 002 SEP 09, 1993
		EQ 30MG BASE	N20070 003 SEP 09, 1993
+		EQ 40MG BASE	N20070 004 SEP 09, 1993
	PARKE DAVIS PHARMS	EQ 10MG BASE	N20070 001 SEP 09, 1993
		EQ 20MG BASE	N20070 002 SEP 09, 1993
		EQ 30MG BASE	N20070 003 SEP 09, 1993
+		EQ 40MG BASE	N20070 004 SEP 09, 1993

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

BS	DRAXIMAGE	N/A	N17881 001 DEC 30, 1987
BS	MERCK SHARP DOHME	N/A	N17881 001 DEC 30, 1987

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
HEPATOLITE

> DLT >	DUPONT	N/A	N18467 001 MAR 16, 1982
> DLT >			
> ADD >	DUPONT MERCK	N/A	N18467 001 MAR 16, 1982
> ADD >			

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION
TECHNESCAN GLUCEPTATE

AP	DRAXIMAGE	N/A	N18272 001 JAN 27, 1982
AP	MERCK SHARP DOHME	N/A	N18272 001 JAN 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION
TECHNESCAN HIDA

	DRAXIMAGE	N/A	N18489 001 OCT 31, 1986
	MERCK	N/A	N18489 001 OCT 31, 1986

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
TECHNESCAN MDP KIT

AP	DRAXIMAGE	N/A	N18035 001
AP	MERCK SHARP DOHME	N/A	N18035 001

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION
DTPA

AP	DRAXIMAGE	N/A	N18511 001 DEC 29, 1989
AP	MERCK	N/A	N18511 001 DEC 29, 1989

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL
AK-SULFUR COLLOID

AP	CIS	N/A	N17858 001
	@	N/A	N17858 001

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
HYTRIN

AB	ABBOTT	EQ 1MG BASE	N20347 001 DEC 14, 1994
AB	+	EQ 2MG BASE	N20347 002 DEC 14, 1994
AB		EQ 5MG BASE	N20347 003 DEC 14, 1994
AB		EQ 10MG BASE	N20347 004 DEC 14, 1994

TERAZOSIN HCL

AB	GENEVA PHARMS	EQ 1MG BASE	N74823 001 MAR 30, 1998
AB		EQ 2MG BASE	N74823 002 MAR 30, 1998
AB		EQ 5MG BASE	N74823 003 MAR 30, 1998
AB		EQ 10MG BASE	N74823 004 MAR 30, 1998

TERBINAFINE

GEL; TOPICAL
LAMISIL

+	NOVARTIS	1%	N20846 001 APR 29, 1998

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM
BX + THERATECH 2.5MG/24HR N20489 001 SEP 29, 1995
+ 2.5MG/24HR N20489 001 SEP 29, 1995

THEOPHYLLINE

CAPSULE; ORAL
ELIXOPHYLLIN
BX FOREST LABS 100MG N85545 001 JUL 31, 1984
BX + 200MG N83921 001 JUL 31, 1984
@ 100MG N85545 001 JUL 31, 1984
@ 200MG N83921 001 JUL 31, 1984

CAPSULE, EXTENDED RELEASE; ORAL
ELIXOPHYLLIN SR
BC FOREST LABS 125MG N86826 001 JAN 29, 1985
BC 250MG N86826 002 JAN 29, 1985
@ 125MG N86826 001 JAN 29, 1985
@ 250MG N86826 002 JAN 29, 1985

TABLET; ORAL
QUIBRON-T
> ADD > + MONARCH PHARMS 300MG N88656 001 AUG 22, 1985
> ADD >
> DLT > + ROBERTS LABS 300MG N88656 001 AUG 22, 1985
> DLT >

TABLET, EXTENDED RELEASE; ORAL
QUIBRON-T/SR
> DLT > BC KING PHARMS 300MG N87563 001 JUN 21, 1983
> DLT >
> ADD > BC MONARCH PHARMS 300MG N87563 001 JUN 21, 1983
> ADD >

THIAMYLAL SODIUM

INJECTABLE; INJECTION
SURITAL
+ PARKE DAVIS 1GM/VIAL N07600 003
+ 5GM/VIAL N07600 005
+ 10GM/VIAL N07600 009
@ PARKEDALE 1GM/VIAL N07600 003
@ 5GM/VIAL N07600 005
@ 10GM/VIAL N07600 009

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
THIORIDAZINE HCL
> ADD > AA PHARM ASSOC 100MG/ML N40213 001 MAY 29, 1998
> ADD >

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION
AGGRASTAT
> ADD > + MERCK EQ 0.05MG BASE/ML N20913 001 MAY 14, 1998
> ADD >
> ADD > + EQ 0.25MG BASE/ML N20912 001 MAY 14, 1998
> ADD >

TOLCAPONE

TABLET; ORAL
TASMAR
ROCHE 100MG N20697 001 JAN 29, 1998
+ 200MG N20697 002 JAN 29, 1998

TOLTERODINE TARTRATE

TABLET; ORAL
DETROL
PHARMACIA AND UPJOHN 1MG N20771 001 MAR 25, 1998
+ 2MG N20771 002 MAR 25, 1998

TORSEMIDE

INJECTABLE; INJECTION

DEMADEX

>DLT<	+	BOEHRINGER MANNHEIM	10MG/ML	N20137 002 AUG 23, 1993
>DLT<				
>ADD<	+	ROCHE	10MG/ML	N20137 002 AUG 23, 1993
>ADD<				

TABLET; ORAL

DEMADEX

>DLT<		BOEHRINGER MANNHEIM	5MG	N20136 001 AUG 23, 1993
>DLT<				
>DLT<			10MG	N20136 002 AUG 23, 1993
>DLT<				
>DLT<			20MG	N20136 003 AUG 23, 1993
>DLT<				
>DLT<	+		100MG	N20136 004 AUG 23, 1993
>DLT<				
>ADD<		ROCHE	5MG	N20136 001 AUG 23, 1993
>ADD<				
>ADD<			10MG	N20136 002 AUG 23, 1993
>ADD<				
>ADD<			20MG	N20136 003 AUG 23, 1993
>ADD<				
>ADD<	+		100MG	N20136 004 AUG 23, 1993
>ADD<				

TRETINOIN

CREAM; TOPICAL

AVITA

AB	+	PENEDERM	0.025%	N20404 003 JAN 14, 1997
AB			0.025%	N20404 003 JAN 14, 1997

GEL; TOPICAL

AVITA

>ADD<	BX	PENEDERM	0.025%	N20400 001 JAN 29, 1998
>ADD<				
>DLT<			0.025%	N20400 001 JAN 29, 1998
>DLT<				

RETIN-A

>DLT<	+	J AND J	0.025%	N17579 002
>ADD<	BX +	JOHNSON AND JOHNSON	0.025%	N17579 002

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

>ADD<		@ ALPHARMA	0.025%	N87797 001 JUN 07, 1982
>ADD<				
>DLT<	AT	NMC	0.025%	N87797 001 JUN 07, 1982
>DLT<				

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HCL

AB	ZENITH GOLDLINE	EQ 1MG BASE	N87612 001 NOV 19, 1982
AB		EQ 2MG BASE	N87613 001 NOV 19, 1982
AB	ZENITH LABS	EQ 1MG BASE	N87612 001 NOV 19, 1982
AB		EQ 2MG BASE	N87613 001 NOV 19, 1982

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

TRIHEXYPHENIDYL HCL

AA	CIRCA	2MG	N40184 001 FEB 06, 1998
AA		5MG	N40184 002 FEB 06, 1998

TROGLITAZONE

TABLET; ORAL

REZULIN

AB	PARKE DAVIS	200MG	N20720 001 JAN 29, 1997
AB		300MG	N20720 003 AUG 04, 1997
AB		400MG	N20720 002 JAN 29, 1997
AB	PARKE DAVIS PHARMS	200MG	N20720 001 JAN 29, 1997
AB		300MG	N20720 003 AUG 04, 1997

TROGLITAZONE

TABLET; ORAL

	REZULIN			
AB	PARKE DAVIS PHARMS	400MG		N20720 002 JAN 29, 1997

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

	TROPICAMIDE			
AT	AKORN	1%		N88447 001 AUG 28, 1985
	@	1%		N88447 001 AUG 28, 1985

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR

	FERTINEX			
	+ SERONO	75 IU/AMP		N19415 002 SEP 18, 1986
	+	150 IU/AMP		N19415 003 SEP 18, 1986
	METRODIN			
	+ SERONO	75 IU/AMP		N19415 002 SEP 18, 1986
	+	150 IU/AMP		N19415 003 SEP 18, 1986

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

	VERAPAMIL HCL			
AP	MARSAM	1.25MG/ML		N72233 001 FEB 26, 1993
AP		2.5MG/ML		N73485 001 SEP 27, 1993
	@	2.5MG/ML		N72233 001 FEB 26, 1993
	@	2.5MG/ML		N73485 001 SEP 27, 1993

VIDARABINE

INJECTABLE; INJECTION

	VIRA-A			
	@ PARKE DAVIS	EQ 187.4MG BASE/ML		N50523 001
	@ PARKEDALE	EQ 187.4MG BASE/ML		N50523 001

OINTMENT; OPHTHALMIC

	VIRA-A			
	+ PARKE DAVIS	3%		N50486 001
	+ PARKEDALE	3%		N50486 001

WATER FOR INJECTION, STERILE

LIQUID; N/A

	STERILE WATER FOR INJECTION IN PLASTIC CONTAINER			
AP	B BRAUN	100%		N19633 001 FEB 29, 1988
AP	MCGAW	100%		N19633 001 FEB 29, 1988

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL
EXCEDRIN (MIGRAINE)
+ BRISTOL MYERS — 250MG;250MG;65MG — N20802 001 JAN 14, 1998

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL
GAVISCON
+ HOECHST MARION RSSL — 80MG;20MG — N18685 001 DEC 09, 1983
80MG;20MG — N18685 001 DEC 09, 1983
+ 160MG;40MG — N18685 002 DEC 09, 1983 > DLT > > DLT > > ADD >
GAVISCON-2
+ HOECHST MARION RSSL — 160MG;40MG — N18685 002 DEC 09, 1983 > ADD >

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL
CHG SCRUB
ECOLAB — 4% — N19258 002 JUL 22, 1986
HUNTINGTON LABS — 4% — N19258 002 JUL 22, 1986
CIDA-STAT
ECOLAB — 2% — N19258 001 JUL 22, 1986
HUNTINGTON LABS — 2% — N19258 001 JUL 22, 1986

CLOTRIMAZOLE

TABLET; VAGINAL
GYNIX
COPLEY PHARM — 100MG — N73249 001 FEB 13, 1998

IBUPROFEN

SUSPENSION; ORAL
CHILDREN'S ADVIL-FLAVORED
+ WHITEHALL ROBINS — 100MG/5ML — N20589 002 NOV 07, 1997
100MG/5ML — N20589 002 NOV 07, 1997

SUSPENSION/DROPS; ORAL
PEDIATRIC ADVIL
+ WHITEHALL ROBINS — 100MG/2.5ML — N20812 001 JAN 30, 1998

TABLET; ORAL
IBUPRIN
GIDEON LABS NJ — 200MG — N71773 001 JUL 16, 1987
@ — 200MG — N71773 001 JUL 16, 1987

TABLET, CHEWABLE; ORAL
JUNIOR STRENGTH MOTRIN
MCNEIL — 100MG — N20601 003 NOV 15, 1996
+ 100MG — N20601 003 NOV 15, 1996

MICONAZOLE NITRATE

CREAM; VAGINAL
MONISTAT 3
+ ADVANCED CARE PRODS — 4% — N20827 001 MAR 30, 1998

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)
NU PHARM — 2% — N74924 001 APR 29, 1998
MINOXIDIL (FOR WOMEN)
NU PHARM — 2% — N74924 002 APR 29, 1998

BLANK

PAGE


UNITED STATES OF AMERICA
GOVERNMENT PRINTING OFFICE
1.0
1.1
1.25
1.4
1.6
2.8
2.5
3.2
2.2
3.6
2.0
1.8
6"

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTROL

+	[redacted]	[redacted]	N20536 001 JUL 03, 1996
+	PHARMACIA AND UPJOHN	15MG/16HR	N20536 001 JUL 03, 1996

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT; ORAL

ZANTAC 75

+	GLAXO WELLCOME	EQ 75MG BASE	N20745 001 FEB 26, 1998

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 5 MAY '98

NO MAY 1998 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
January 1998 through May 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
1,5-(Butylimino) -1,5 dideoxy,D-glucitol TN=	Treatment of Fabry's disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington Oxfordshire OX14 3YS UK, DD=05/12/1998
1,5-(Butylimino) -1,5 dideoxy,D-glucitol TN=	Treatment of Gaucher disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington Oxfordshire OX14 3YS UK, DD=05/29/1998
Aitretinoin TN= Panretin	For the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive San Diego, CA 92121 DD=03/24/1998
Aldesleukin TN= Proleukin	Treatment of metastatic melanoma.	Chiron Corporation 4560 Horton Street Emeryville, CA 94608 DD=09/10/1996 MA=01/09/1998
Amifostine TN= Ethyol	Reduction of the incidence and severity of radiation-induced xerostomia.	U.S. Bioscience, Inc. One Tower Bridge 100 Front Street, Suite 400 Conshohocken, PA 19428 DD=05/12/1998
Arsenic trioxide TN=	Treatment of acute promyelocytic leukemia.	PolaRx, Inc. 787 7th Ave., 48th Floor New York, NY 10019 DD=03/03/1998

Orphan Product Designations and Approvals List
January 1998 through May 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Basiliximab TN= Simulect	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=12/12/1997 MA=05/12/1998
Beclomethasone dipropionate TN=	For oral administration in the treatment of intestinal graft-versus-host disease.	George B. McDonald, M.D. Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North (SC-113); PO Box 19024 Seattle, WA 98109 DD=03/27/1998
Benzydamine hydrochloride TN= Tantum	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge, NJ 07661 DD=05/18/1998
Bindarit TN=	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge, NJ 07661 DD=02/03/1998
Carbamylglutamic acid TN=	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe Immeuble "Le Guillaumet" 60 avenue du President Wilson 92046 Paris France DD=01/20/1998
Corticotropin-releasing factor, human TN= Xerecept	Treatment of peritumoral brain edema.	Neurobiological Technologies, Inc. 1387 Marina Way South Richmond, CA 94804 DD=04/06/1998
Dimethylsulfoxide TN=	Treatment of palmar-plantar erythrodysesthesia syndrome.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/06/1998

Orphan Product Designations and Approvals List
January 1998 through May 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Filgrastim TN= Neupogen	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc. 1840 DeHavilland Drive Thousand Oaks, CA 91320 DD=11/07/1996 MA=04/02/1998
Fructose-1,6-diphosphate TN=	Treatment of painful vaso-occlusive episodes associated with sickle cell disease.	Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, CA 92008 DD=05/29/1998
Hydroxyurea TN= Droxia	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute P.O. Box 4000 Princeton, NJ 08543 DD=10/01/1990 MA=02/25/1998
L-baclofen TN=	Treatment of trigeminal neuralgia.	Pharmascience, Inc. 8400 Darnley Road Montreal, Quebec Canada H4T 1M4 DD=01/06/1998
Lepirudin TN= Refluden	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel Frankfurt am Main Germany DD=02/13/1997 MA=03/06/1998
Liposomal Cyclosporin A TN= Cyclospire	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Vernon Knight, M.D. Baylor College of Medicine, Dept. of Molecular Physiology One Baylor Plaza Houston, TX 77030 DD=04/30/1998
Pentostatin TN=	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc. Two Annbel Lane, Suite 220 San Ramon, CA 94583 DD=03/27/1998
Phenylacetate TN=	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or	Targon Corporation 307 College Road East Princeton, NJ 08540 DD=03/06/1998

Orphan Product Designations and Approvals List
January 1998 through May 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Pilocarpine HCl TN= Salagen	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc. 9900 Bren Road East Suite 300E Minneapolis, MN 55343 DD=02/28/1992 MA=02/11/1998
Recombinant humanized monclonal antibody 5c8	Treatment of immune thrombocytopenic purpura.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=02/03/1998
Recombinant humanized monoclonal antibody 5c8	Treatment of systemic lupus erythematosus.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=02/18/1998
Rifaximin TN= Normix	Treatment of hepatic encephalopathy.	Salix Pharmaceuticals, Inc. 3600 W. Bayshore Road Palo Alto, CA 94303 DD=02/10/1998
S-adenosylmethionine TN=	Treatment of AIDS-myelopathy.	Di Rocco, Alessandro M.D. Beth Israel Medical Center, Dept. of Neurology Philips Building, Suite 2Q; 10 Union Square New York, NY 10003 DD=04/30/1998
Sacrosidase TN= Sucraid	Treatment of congenital sucrase-isomaltase deficiency.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=12/10/1993 MA=04/09/1998
Sodium phenylbutyrate TN=	For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Targon Corporation 307 College Road East Princeton, NJ 08540 DD=04/24/1998
TAK-603 TN=	Treatment of Crohn's disease.	TAP Holdings Inc. 2355 Waukegan Road Deerfield, IL 60015 DD=05/13/1998

Orphan Product Designations and Approvals List
January 1998 through May 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Tacrolimus TN= Prograf	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=04/06/1998
Tetrabenazine TN=	Treatment for moderate/severe tardive dyskinesia.	Lifehealth Limited Richmond House, Old Brewery Court, Sandyford Road Newcastle upon Tyne NE2 1XG England DD=05/12/1998
Thalidomide TN=	Treatment of primary brain malignancies.	EntreMed, Inc. 9610 Medical Center Drive, Suite 200 Rockville, MD 20850 DD=02/27/1998
Thymalfasin TN= Zadaxin	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Blvd. San Mateo, CA 94404 DD=01/08/1998
Tiapride TN=	Treatment of Tourette's syndrome.	Synthelabo Research, Inc. 400 Plaza Drive Secaucus, NJ 07094 DD=04/21/1998
Transgenic human alpha 1 antitrypsin TN=	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland U.K., DD=03/06/1998

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MAY 1998 ADDITIONS

PATENT AND EXCLUSIVITY TERMS PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 18TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING *SCHEDULE*

D-38	CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
D-39	CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM " ...1/2-1 HOUR BEFORE EATING..." TO "...RIGHT BEFORE EATING OR UP TO 60 MIN BEFORE CONSUMING..."
D-40	ONCE-A-DAY DOSING REGIMEN
D-41	DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30 MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS

NEW INDICATION

I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOICATED WITH ALLERGIC AND NONALLERGIC PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-228	PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60 MIN PRIOR TO A MEAL
I-229	PRILOSEC (OMEPRAZOLE), AMOXICILLIN AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
I-230	IN COMBINATION WITH CISPLATIN, FOR THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION

PATENT USE CODE

U-215	TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C, BY ADMINISTERING AN AGONIST OF LR-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219	TREATMENT OF PARKISON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGETS DISEASE USING ACTONEL
U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	METHOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
U-231	USE IN PARKINSON'S DISEASE
U-232	METHOD OF TREATING MIGRAINE
U-233	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234	METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235	METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020802	001	ACETAMINOPHEN;EXCEDRIN (MIGRAINE)				NP	JAN 14, 2001
	020059	001	ADENOSINE;ADENOSCAN	5070877	DEC 10, 2008	U-116		
				5731296	MAR 24, 2015	U-221		
	019787	001	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	019787	002	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	019787	003	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	020420	001	ARBUTAMINE HYDROCHLORIDE;GENESA	5108363	APR 28, 2009	U-220		
				5234404	AUG 10, 2010	U-220		
				5395970	MAR 07, 2012			
>ADD>	020702	001	ATORVASTATIN CALCIUM;LIPITOR				I-218	JUL 10, 2001
>ADD>							I-219	JUL 10, 2001
>ADD>	020702	002	ATORVASTATIN CALCIUM;LIPITOR				I-218	JUL 10, 2001
>ADD>							I-219	JUL 10, 2001
>ADD>	020702	003	ATORVASTATIN CALCIUM;LIPITOR				I-218	JUL 10, 2001
>ADD>							I-219	JUL 10, 2001
	020114	001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	NOV 01, 2010	U-207		
	017573	001	BECLOMETHASONE DIPROPIONATE;VANCERIL	4364923	DEC 21, 1999			
	018521	001	BECLOMETHASONE DIPROPIONATE;VANCENASE	4364923	DEC 21, 1999			
	020486	001	BECLOMETHASONE DIPROPIONATE;VANCERIL DOUBLE STRENGTH	4364923	DEC 21, 1999			
	019408	001	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
	020816	001	BRINZOLAMIDE;AZOPT	5240923	AUG 31, 2010	U-224	NCE	APR 01, 2003
				5378703	AUG 31, 2010	U-224		
				5461081	OCT 24, 2012	U-225		
>ADD>	020554	001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
>ADD>	020611	001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
	020313	002	CALCITONIN, SALMON;MIACALCIN	5733569	MAR 31, 2015	U-227		
>ADD>	020521	001	CALFACTANT;INFASURF				NCE	JUL 01, 2003
>ADD>	020838	001	CANDESARTAN CILEXETIL;ATACAND	5703110	APR 18, 2011		NCE	JUN 04, 2003
>ADD>				5705517	APR 18, 2011			
				5196444	APR 18, 2011	U-3		
				5508297	FEB 24, 2014	U-3		
				5534534	JUL 09, 2013			
>ADD>	020838	002	CANDESARTAN CILEXETIL;ATACAND	5703110	APR 18, 2011		NCE	JUN 04, 2003
>ADD>				5705517	APR 18, 2011			
				5196444	APR 18, 2011	U-3		
				5508297	FEB 24, 2014	U-3		
				5534534	JUL 09, 2013			
>ADD>	020838	003	CANDESARTAN CILEXETIL;ATACAND	5703110	APR 18, 2011		NCE	JUN 04, 2003
>ADD>				5705517	APR 18, 2011			
				5196444	APR 18, 2011	U-3		
				5508297	FEB 24, 2014	U-3		
				5534534	JUL 09, 2013			
>ADD>	020838	004	CANDESARTAN CILEXETIL;ATACAND	5703110	APR 18, 2011		NCE	JUN 04, 2003
>ADD>				5705517	APR 18, 2011			
				5196444	APR 18, 2011	U-3		
				5508297	FEB 24, 2014	U-3		
				5534534	JUL 09, 2013			
	020896	001	CAPECITABINE;XELODA				NCE	APR 30, 2003
	020896	002	CAPECITABINE;XELODA				NCE	APR 30, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020712	001	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
	020712	002	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
>ADD>	020297	001	CARVEDILOL;COREG	5760069	JUN 07, 2015	U-233		
				4503067	MAR 05, 2007	U-3		
>ADD>	020297	002	CARVEDILOL;COREG	5760069	JUN 07, 2015	U-233		
				4503067	MAR 05, 2007	U-3		
>ADD>	020297	003	CARVEDILOL;COREG	5760069	JUN 07, 2015	U-233		
				4503067	MAR 05, 2007	U-3		
>ADD>	020297	004	CARVEDILOL;COREG	5760069	JUN 07, 2015	U-233		
	020774	001	CHLORHEXIDINE GLUCONATE;PERIOCHIP				NP	MAY 15, 2001
>ADD>	020238	002	CIMETIDINE;TAGAMET HB				D-41	JUN 05, 2001
	020369	001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	JUN 02, 2004	U-223	NDF	MAR 30, 2001
	020805	001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO HC	4670444	DEC 09, 2003		NC	FEB 10, 2001
				4844902	FEB 11, 2008			
	020780	001	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
	020780	002	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
	020839	001	CLOPIDOGREL BISULFATE;PLAVIX	4529596	JUL 05, 2003			
				4847265	FEB 12, 2008			
				5576328	JAN 31, 2014			
	017922	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	017922	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	017922	003	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	018938	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	018938	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	019955	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013		I-40	MAR 25, 2001
	019955	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013		I-40	MAR 25, 2001
	020713	001	DESOGESTREL;MIRCETTE				NP	APR 22, 2001
	020037	001	DICLOFENAC SODIUM;VOLTAREN				I-213	FEB 25, 2001
>ADD>	020148	001	DIHYDROERGOTAMINE MESYLATE;MIGRANAL	4758423	JUL 31, 2001			
>ADD>				4462983	JUL 31, 2001	U-227		
>ADD>				5169849	DEC 08, 2009			
						U-227		
	020401	001	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	002	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	003	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	004	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	005	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020869	001	DORZOLAMIDE HYDROCHLORIDE;COSOPT				NC	APR 07, 2001
	020164	001	ENOXAPARIN SODIUM;LOVENOX				I-217	JAN 30, 2001
							I-222	MAR 27, 2001
	020164	002	ENOXAPARIN SODIUM;LOVENOX				I-222	MAR 27, 2001
							I-217	JAN 30, 2001
	020738	004	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3		
	020738	005	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3		
	020718	001	EPTIFIBATIDE;INTEGRILIN				NCE	MAY 18, 2003
	020718	002	EPTIFIBATIDE;INTEGRILIN				NCE	MAY 18, 2003
	020375	003	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
	083209	001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
	086715	001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020363	001	FAMCICLOVIR;FAMVIR				NCE	JUN 29, 1999
	020786	001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	4254129	APR 10, 1999			
				5375693	AUG 03, 2012			
				5578610	NOV 26, 2013			
	020180	001	FINASTERIDE;PROSCAR				I-221	MAR 20, 2001
	018830	001	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	002	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	003	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	004	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018554	001	FLUTAMIDE;EULEXIN	4472382	SEP 18, 2001	U-24		
				5712251	SEP 18, 2001	U-216		
	020121	001	FLUTICASONE PROPIONATE;FLONASE				I-224	OCT 31, 2000
	020450	001	FOSPHENYTOIN SODIUM;CEREBYX	4260769	APR 07, 1999			
	020695	001	GREPAFLOXACIN HYDROCHLORIDE;RAXAR	5563138	OCT 08, 2013			
	020818	001	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
							NC	MAR 06, 2001
	020818	002	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
							NC	MAR 06, 2001
	020716	001	HYDROCODONE BITARTRATE;VICOPROFEN	4587252	DEC 18, 2004	U-55		
	016295	002	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
	016295	003	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
	016295	004	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
	020812	001	IBUPROFEN;PEDIATRIC ADVIL				NP	JUN 16, 1998
>ADD>	020903	001	INTERFERON ALFA-2B;REBETRON	4530901	JUL 23, 2002		NP	JUN 03, 2001
>ADD>				4211771	JUL 08, 1999	U-234		
>ADD>				5767097	JAN 23, 2016	U-235		
	020393	001	IPRATROPIUM BROMIDE;ATROVENT				I-223	APR 01, 2001
	019927	001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003			
	020406	001	LANSOPRAZOLE;PREVACID				I-227	MAR 12, 2001
	020406	002	LANSOPRAZOLE;PREVACID				I-227	MAR 12, 2001
	020807	001	LEPIRUDIN;REFLUDAN	5180668	JAN 19, 2010		ODE	MAR 06, 2005
							NCE	MAR 06, 2003
	019732	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
	020011	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
	020517	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
	020263	002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020708	001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5716640	SEP 02, 2013			
	020517	002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	5716640	SEP 02, 2013			
	019941	001	LIDOCAINE;EMLA				I-215	FEB 04, 2001
	020962	001	LIDOCAINE;EMLA				NP	FEB 04, 2001
	020606	001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5716641	MAY 21, 2012	U-226		
	020803	001	LOTEPREDNOL ETABONATE;ALREX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			
	020583	001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020841	001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			
	019832	003	NAFENIDE ACETATE;SULFAMYLON				NDF	JUN 05, 2001
							ODE	JUN 05, 2005
	019618	001	MESALAMINE;ROWASA	4657900	APR 14, 2004			
				RE33239	MAY 12, 2004			
	020208	001	METRONIDAZOLE;METROGEL-VAGINAL				D-40	MAY 16, 2000
	020827	001	MICONAZOLE NITRATE;MONISTAT 3				NP	MAR 30, 2001
	020762	001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	4472393	SEP 18, 2001			
	020830	001	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003
	020829	002	MONTELUKAST SODIUM;SINGULAR	5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003
	020763	001	NARATRIPTAN HYDROCHLORIDE;AMERGE				NCE	FEB 10, 2003
	020763	002	NARATRIPTAN HYDROCHLORIDE;AMERGE				NCE	FEB 10, 2003
	020536	001	NICOTINE;NICOTROL	4915950	FEB 12, 2008			
	020555	001	NIZATIDINE;AXID AR				I-220	APR 01, 2001
							D-39	APR 01, 2001
	020799	001	OFLOXACIN;FLOXIN				NDF	DEC 16, 2000
>ADD<	019810	001	OMEPRAZOLE;PRILOSEC				I-229	JUN 29, 2001
>ADD<	019810	002	OMEPRAZOLE;PRILOSEC				I-229	JUN 29, 2001
	020262	001	PACLITAXEL;TAXOL				I-226	APR 09, 2001
>ADD<							I-230	JUN 30, 2001
	020819	001	PARICALCITOL;ZEMPLAR				NCE	APR 17, 2003
	020237	001	PILOCARPINE HYDROCHLORIDE;SALAGEN				ODE	FEB 11, 2005
							I-212	FEB 11, 2001
>ADD<	020667	001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
>ADD<				4843086	JUN 27, 2006	U-231		
>ADD<	020667	002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
>ADD<				4843086	JUN 27, 2006	U-231		
>ADD<	020667	003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
>ADD<				4843086	JUN 27, 2006	U-231		
>ADD<	020667	004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	48	DEC 12, 2006			
>ADD<					27, 2006	U-231		
>ADD<	020667	005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	488	DEC 12, 2006			
>ADD<				4843086	JUN 27, 2006	U-231		
	019898	002	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
	019898	003	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
	019898	004	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
	019781	001	PROGESTERONE;PROMETRIUM				NP	MAY 14, 2001
	019627	002	PROPOFOL;DIPRIVAN	5731355	MAR 22, 2015	U-217		
				5731356	MAR 22, 2015	U-218		
	020815	001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2001			
				5393763	JUL 28, 2012	U-114		
				5457117	JUL 28, 2012	U-114		
				5478847	MAR 02, 2014	U-114		
>ADD<	020520	001	RANITIDINE HYDROCHLORIDE;ZANTAC 75				I-228	JUN 08, 2001
>ADD<	021024	001	RIFAPENTINE;PRIFTIN				NCE	JUN 22, 2003
>ADD<							ODE	JUN 22, 2005
	020835	001	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U-222	NCE	MAR 27, 2003
	020272	005	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009		D-37	OCT 17, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020772	001	SACROSIDASE;SUCRAID				ODE	APR 09, 2005
							NCE	APR 09, 2003
	020236	001	SALMETEROL XINAFOATE;SEREVENT	5126375	FEB 12, 2008		I-216	FEB 05, 2001
>ADD>	020692	001	SALMETEROL XINAFOATE;SEREVENT	D342994	JAN 04, 2008			
				5225445	FEB 12, 2008	U-211		
				5380922	JAN 10, 2012			
				5590645	MAR 01, 2011			
				5126375	FEB 12, 2008			
	020895	001	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	020895	002	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	020895	003	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	019676	001	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 29, 2004
	019676	002	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 29, 2004
	020181	001	SOYBEAN OIL;LIPOSYN III 30%				NP	JAN 13, 2001
>ADD>	020626	001	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
>ADD>				5307953	DEC 02, 2012			
>ADD>				5554639	SEP 10, 2013	U-232		
>ADD>				5705520	DEC 10, 2011	U-232		
>ADD>	020626	002	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
>ADD>				5307953	DEC 02, 2012			
>ADD>				5554639	SEP 10, 2013	U-232		
>ADD>				5705520	DEC 10, 2011	U-232		
>ADD>	020626	003	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
>ADD>				5307953	DEC 02, 2012			
>ADD>				5554639	SEP 10, 2013	U-232		
>ADD>				5705520	DEC 10, 2011	U-232		
	020791	001	TESTOSTERONE;TESTODERM	4379454	FEB 17, 2001			
	020912	001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAR 08, 2011	U-230	NCE	MAY 14, 2003
				5658929	MAR 08, 2011			
				5733919	OCT 23, 2016			
	020913	001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAR 08, 2011	U-230	NCE	MAY 14, 2003
				5658929	MAR 08, 2011			
				5733919	OCT 23, 2016			
	020697	001	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
				5476875	DEC 19, 2012	U-219		
	020697	002	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
				5476875	DEC 19, 2012	U-219		
	020771	001	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
	020771	002	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
	020137	002	TORSEMIDE;DEMADEX				D-38	FEB 13, 2001
	020528	001	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020528	002	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020528	003	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020675	001	URSODIOL;URSO	4859660	AUG 22, 2006			
>ADD>	020699	001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
>ADD>	020699	002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
>ADD>	020699	003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
>ADD>	020699	004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			

New 18th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC E)UIVALENCE EVALUATIONS

18TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 80128

Charge your order. It's easy!

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, ADP,** and the monthly Cumulative Supplements, for $77.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐ – ☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

Company or personal name

Additional address/attention line

Street address

City, State, ZIP Code

( ) Daytime phone including area code

Purchase Order No. (optional)

(Credit card expiration date)

Thank you for your order!

(Authorizing Signature) (11/97)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.


UNITED STATES OF AMERICA
GOVERNMENT PRINTING OFFICE
1.0
1.1
1.25
1.4
1.6
1.8
2.0
2.2
2.5
2.8
3.2
3.6
4.0
6"